

SECTOR CAPITAL FUNDS PLC

*(A company incorporated with limited liability as an open-ended umbrella investment company
with variable capital under the laws of Ireland)*

ANNUAL REPORT AND AUDITED FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024

Registration No. 489443

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

TABLE OF CONTENTS

	Page
General Information.....	2
Directors' Report.....	3
Depositary's Report.....	6
Investment Manager's Report.....	7
Independent Auditors' Report.....	9
Balance Sheet	12
Profit and Loss Account	14
Statement of Changes in Net Assets attributable to holders of Redeemable Participating Shares.....	16
Schedule of Investments	17
Notes to the Financial Statements.....	21
Significant Portfolio Movements (Unaudited).....	46
Remuneration Information (Unaudited)	48
Additional disclosures in respect of The Sustainable Finance Disclosure Regulation ("SFDR") (Unaudited).....	49

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

GENERAL INFORMATION

Directors

Michael Boyce (*Irish*)^
Lars Tell (*Swedish*)
Conor Walsh (*Irish*)^

^Independent non-executive Director

Manager

Sector Fund Services AS
Kristian Augusts gate 15 C
N-0164 Oslo
Norway

Investment Manager

Sector Healthcare Value Fund
Sector Gamma AS
Kristian Augusts gate 15 c
N-0164 Oslo
Norway

Investment Manager

Sector Emerging Markets Equity Fund
Cusana Capital LLP*
Heathmans House
19 Heathmans Road London SW64TJ
United Kingdom

Administrator, Registrar and Transfer Agent

BNY Mellon Fund Services (Ireland) Designated Activity
Company
Riverside Two
Sir John Rogerson's Quay
Grand Canal Dock
Dublin 2
Ireland

Depository

The Bank of New York Mellon SA/NV, Dublin Branch
Riverside Two
Sir John Rogerson's Quay
Grand Canal Dock
Dublin 2
Ireland

Registered Office

32 Molesworth Street
Dublin 2
Ireland

Independent Auditors

Deloitte Ireland LLP
Chartered Accountants and Statutory Audit Firm
Deloitte & Touche House
Earlsfort Terrace
Dublin 2
Ireland

Legal Advisers to the Company (*advisers as to Norwegian law*)

BAHR
Advokatfirmaet BAHR AS
Tjuvholmen allé 16
NO-0252 Oslo
Norway

Legal Advisers to the Company (*advisers as to Irish law*)

Maples and Calder (Ireland) LLP
75 St. Stephen's Green
Dublin 2
Ireland

Global Distributor

Sector Capital AS
Kristian Augusts gate 15 c
N-0164 Oslo
Norway

Company Secretary

MFD Secretaries Limited
32 Molesworth Street
Dublin 2
Ireland

*Effective 18 April 2024, Cusana Capital LLP replaced Capricorn Fund Managers Limited as Investment Manager to Sector Emerging Markets Equity Fund.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

DIRECTORS' REPORT

The Directors present to the shareholders their annual report and the audited financial statements of Sector Capital Funds plc (the "Company") for the financial year 1 January 2024 to 31 December 2024.

Principal Activities and Review of Business

The Company was incorporated and registered in Ireland under the Companies Act 2014 as an open-ended umbrella investment company with variable capital and with segregated liability between sub-funds on 27 September 2010 with registered number 489443. The net assets of the Company were USD542,404,426 on 31 December 2024 (31 December 2023: USD490,201,887).

The Company was authorised by the Central Bank of Ireland pursuant to European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (as amended) and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019 (as amended) (the "Regulations").

As at 31 December 2024, the Company has two funds in existence (31 December 2023: two), Sector Emerging Markets Equities Fund and Sector Healthcare Value Fund.

Sector Emerging Markets Equities Fund commenced trading on 1 September 2023. The base currency of Sector Emerging Markets Equities Fund is United States Dollars ("USD"). As at 31 December 2024 four classes are subscribed to in the Fund (31 December 2023: three), S EUR Shares, S GBP Shares, S NOK Shares and S USD Shares.

Sector Healthcare Value Fund commenced trading on 17 November 2010. The base currency of Sector Healthcare Value Fund is USD. As at 31 December 2024, fourteen classes are subscribed to in the Fund (31 December 2023: fourteen), A EUR Shares, A NOK Shares, A USD Shares, B EUR Shares, B NOK Shares, B SEK Shares, B USD Shares, X USD Shares, X EUR Shares, Y EUR Shares, Y GBP Shares, Y USD Shares, E NOK Shares and E USD Shares.

Results, Activities and Future Developments

The results of operations are set out on page 13. A detailed review of the business and future developments for the Funds is contained in the Investment Manager's Report on page 7.

Statement of Directors' Responsibilities

The Directors are responsible for preparing the Directors' report and the financial statements in accordance with the Companies Act 2014 and the applicable Regulations.

Irish company law requires the Directors to prepare financial statements for each financial year. Under the law, the Directors have elected to prepare the financial statements in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland ("relevant financial reporting framework"). Under company law, the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the Company as at the financial year end date and of the profit or loss of the Company for the financial year and otherwise comply with the Companies Act 2014.

In preparing those financial statements, the Directors are required to:

- select suitable accounting policies for the Company financial statements and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with the applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Directors are responsible for ensuring that the Company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the Company, enable at any time the assets, liabilities, financial position and profit or loss of the Company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

DIRECTORS' REPORT (Continued)

Audit Information Statement

So far as each of the Directors in office at the date of approval of the financial statements are aware:

- there is no relevant audit information of which the Company's auditors are unaware; and
- the Directors have taken all the steps that they ought to have taken as Directors in order to make themselves aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of Section 330 of the Companies Act 2014.

Accounting Records

The Directors believe that they have complied with the requirements of Section 281 to 285 of the Companies Act 2014 with regard to the accounting records by employing the resources of an administrator, BNY Mellon Fund Services (Ireland) Designated Activity Company (the "Administrator"). During the financial year the accounting records of the Company were maintained at the offices of the Administrator, BNY Mellon Fund Services (Ireland) Designated Activity Company, Riverside Two, Sir John Rogerson's Quay, Grand Canal Dock, Dublin 2.

Fair Value Directive

It is the opinion of the Board of Directors that the information required by the European Communities (Fair Value Accounting) Regulations 2004, in relation to the use by the Company of financial instruments and the financial risk management objectives and policies of the Company and the exposures of the Company to market risk, currency risk, interest rate risk, liquidity risk and credit risk is contained in the Investment Manager's Report and note 7.

Significant events during the financial year

Effective 18 April 2024, Cusana Capital LLP replaced Capricorn Fund Managers Limited as Investment Manager to Sector Emerging Markets Equity Fund.

Effective 18 April 2024, a new supplement was noted by the Central Bank for Sector Emerging Markets Equities Fund noting the change in Investment Manager noted above and re-designating the fund as an Article 8 fund under the SFDR Regulations.

There were no other significant events during the financial year.

Significant events after the balance sheet date

There were no significant events after the balance sheet date.

Business Continuity Planning

All relevant third party service providers, including the Investment Manager, have confirmed to the Board they have applied their contingency plans to ensure operational continuity in line with regulatory obligations of the Company. No operational disturbances have been identified as of now.

Directors

Michael Boyce
Lars Tell
Conor Walsh

Directors' and Secretary's Interests

The Directors and Secretary and their families had no interest in the shares of the Company at 31 December 2024, other than as disclosed below:

As at 31 December 2024, Lars Tell, Director of the Company held 374 A NOK shares in Sector Healthcare Value Fund (31 December 2023: 374 A NOK).

Dividends

Under the Articles of Association dividends may be paid out of the profits. During the financial years ended 31 December 2024 and 31 December 2023, no dividends were paid.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

DIRECTORS' REPORT (Continued)

Corporate Governance Statement

The Company is subject to and complies with the Regulations.

The Board has adopted the voluntary Irish Funds ("IF") Corporate Governance Code for Irish domiciled Collective Investment Schemes and Management Companies, issued 14 December 2011 (the "Code") with effect from 11 December 2012. The Board has reviewed and assessed the measures included in the Code and considers its corporate governance practices and procedures since the adoption of the Code as consistent therewith.

The Company is subject to corporate governance practices imposed by:

1. The Irish Companies Acts 2014 and the Regulations which are available for inspection at the registered office of the Company and may also be obtained at www.irishstatutebook.ie.
2. The Articles of Association of the Company which are available for inspection at the registered office of the Company and at the Companies Registration Office in Ireland.
3. The Central Bank of Ireland in their Regulations which can be obtained from the Central Bank of Ireland's website at: www.centralbank.ie and are available for inspection at the registered office of the Company.

Decision not to establish an Audit Committee


The Directors have decided not to establish an audit committee pursuant to section 167(2) (b) of the Companies Act 2014. This has been decided on the basis of the following:

- a) the nature, scale and complexity of the Company's business range of services and activities undertaken in the course of that business;
- b) the resources available to the Company and the resources and expertise of the various third parties engaged to support the Company and carry out certain functions on its behalf; and
- c) the procedures in place for the review, approval and circulation of the audited financial accounts and statements which are appropriate for a self-managed investment company pursuant to the Regulations.

Independent Auditors


Deloitte Ireland LLP, Chartered Accountants and Statutory Audit Firm, have expressed their willingness to continue in office in accordance with Section 383(2) of the Companies Act 2014.

On behalf of the Board of Directors

Signed by:

E1CE5842BDAF402

Michael Boyce, Director

Date: 26 March 2025

DocuSigned by:

60A8A95D67E74E3

Conor Walsh, Director



The Bank of New York Mellon SA/NV,
Dublin Branch
Riverside Two, Sir John Rogerson's Quay
Grand Canal Dock, Dublin 2, D02 KV60, Ireland.

T +353 1 900 7920

**REPORT FROM THE DEPOSITARY TO THE SHAREHOLDERS
DATED 26 MARCH 2025**

For the period from 01 January 2024 to 31 December 2024 (the “**Period**”)

The Bank of New York Mellon SA/NV, Dublin Branch (the “**Depositary**” “**us**”, “**we**”, or “**our**”) has enquired into the conduct of Sector Capital Funds plc (the “**Company**”) for the Period, in its capacity as Depositary to the Company.

This report including the opinion has been prepared for and solely for the shareholders in the Company, in accordance with our role as Depositary to the Company and for no other purpose. We do not, in giving this opinion, accept or assume responsibility for any other purpose or to any other person to whom this report is shown.

Responsibilities of the Depositary

Our duties and responsibilities are outlined in Regulation 34 of the of the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (S.I. No 352 of 2011), as amended (the “**Regulations**”).

Our report shall state whether, in our opinion, the Company has been managed in that period in accordance with the provisions of the Company’s constitutional documentation and the Regulations. It is the overall responsibility of the Company to comply with these provisions. If the Company has not been so managed, we as Depositary must state in what respects it has not been so managed and the steps which we have taken in respect thereof.

Basis of Depositary Opinion

The Depositary conducts such reviews as it, in its reasonable opinion, considers necessary in order to comply with its duties and to ensure that, in all material respects, the Company has been managed (i) in accordance with the limitations imposed on its investment and borrowing powers by the provisions of its constitutional documentation and the appropriate regulations and (ii) otherwise in accordance with the Company’s constitutional documentation and the appropriate regulations.

Opinion

In our opinion, the Company has been managed during the Period, in all material respects:

- (i) in accordance with the limitations imposed on the investment and borrowing powers of the Company by the constitutional documentation and the Regulations; and
- (ii) otherwise in accordance with the provisions of the constitutional documentation and the Regulations.

Saskia Van Goethem

For and on Behalf of
The Bank of New York Mellon SA/NV, Dublin Branch,

Registered in Ireland No. 907126, VAT No. IE9578054E

The Bank of New York Mellon SA/NV, trading as The Bank of New York Mellon SA/NV, Dublin Branch is authorised by the National Bank of Belgium.

The Bank of New York Mellon SA/NV, Boulevard Anspachlaan 1, B-1000 Brussels Belgium – Tel. (32) 2 545 81 11, V.A.T. BE 0806.743.159-RPM-RPR Brussels Company No. 0806.743.159. The Bank of New York Mellon SA/NV is a Belgian limited liability company, authorized and regulated as a significant credit institution by the European Central Bank and the National Bank of Belgium under the Single Supervisory Mechanism and by the Belgian Financial Services and Markets Authority.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

INVESTMENT MANAGER'S REPORT

Sector Emerging Markets Equities Fund

2024 Performance Review

We are delighted to have delivered a year in which the philosophy and process of the Cusana EM strategy has borne fruit, continuing the long-term outperformance of the strategy from its home at previous firms. Having continued to focus only on selecting the best companies from the outstanding EM opportunity set without the distraction from the benchmark-centric structure of the EM asset class, the portfolio delivered +23% absolute and +15% relative performance. This was driven predominantly by superior cashflow-backed earnings growth. We are pleased to offer an attractive and diversifying source of returns from an increasingly concentrated US market leadership by the Mag 7.

The overarching driver of performance this year has been alpha. Just over 70% of the Fund's 2024 outperformance was down to security selection. The residual was equally split between country allocation and currency effects.

A core component of this alpha-driven performance has been the performance of many stocks which were initiated during 2H23, following our reduction in exposure to China. The portfolio as shaped through this period has performed well: 75% of the allocation initiated through 2H23 has delivered >20% returns and several of these positions have delivered >50% returns since purchase. This exemplifies the flexibility of the strategy and the strength of maintaining an active watchlist of companies competing for capital: when the changing investment environment necessitates change, we have ready-made candidates offering attractive returns.

The strong performance of the positions added through late 2023 has been complimented by longstanding strategy stalwarts – several of which we have owned for over a decade, as well as some newer additions through 2024. This is reflected in the complexion of portfolio returns this year:

-70% of the Fund NAV delivered a positive return in 2024; 28% of the Fund by NAV was up more than 50%; 8% of the Fund by NAV doubled or more.

-The Fund has benefited from a multitude of performance drivers: for example, there are 5 different geographies, and 5 different thematic drivers represented amongst the positions that increased by 50% or more.

-26% of the Fund NAV delivered a negative return in 2024; just 3% of the Fund by NAV declined by 25% or more.

Key to the Fund's negligible drawdown last year was the avoidance of many of the EM banana skins of 2024, which we believe to be reflective of our forward-looking perspective on risk. We avoided the technology hardware companies that had been bid up on AI hype, but where the sustainable advantage was unlikely to develop further. Examples of these laggards include Samsung Electronics which we have believed to have less potential than that implied by the market price. For many years we have avoided Indian stocks where we believe governance and controlling shareholders to be unreliable partners for minority investors – for instance the Adani group. Such concerns have manifested this year, but the Fund has avoided the impact.

Outlook

We do not buy stocks just because they did well over the last 10 years. We need to look forward thoughtfully and creatively when assessing future prospects with a 5+ year horizon.

Rapid (and constant) technological and societal change means that extrapolation can prove very costly to the backward-looking investor. Some of the biggest winners in the portfolio in the last 12 months, but also over the long term, have come from recognising inflection points in business economics. Importantly, these are structural inflections. Not cyclical.

As we look across the expected returns of our portfolio holdings, the asymmetry between the bull-case and bear-case return expectations is striking. All our bottom-up assumptions are firmly grounded with regards to sustainable asset turns, margins and cash conversion. In turn, these are a function of competitive moats and comprehensive analysis of each businesses' value chain. All our investments enjoy access to great growth opportunities with governance that we assess as highly resilient in the Cusana investment checklist. In short, we feel that this asymmetry is well justified in our research.

We look forward to 2025 and to continuing to develop consistently high returns for our clients.

Sustainable Finance Disclosure Regulation

For the purposes of SFDR, the Fund is classified as an Article 8 Fund. This Fund promotes the environmental and social characteristics through the application of its investment strategy and the integration of environmental, social and governance (ESG) factors into the IM's fundamental bottom-up research process. However, the Fund did not commit to make a minimum proportion of sustainable investments and the investments underlying this financial product do not take into account the EU criteria for environmentally sustainable economic activities. More detailed product specific disclosures can be found in Fund's Annex IV document

Cusana Capital LLP
March 2025

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

INVESTMENT MANAGER'S REPORT (Continued)

Sector Healthcare Value Fund

Sector Healthcare Value Fund returned 1.3 percent in 2024, slightly ahead of the global healthcare sector¹, which returned 1.1 percent in the same period.

The top performing holdings in 2024 were UCB, Gilead and Tenet. The value of UCB more than doubled, on the back of strong new product launch trends. The Fund sold its UCB holding in December, a position that was initiated in late 2020. The top losing positions in 2024 were CVS, Biogen and BioMarin. On a relative basis, it was costly not to own Eli Lilly and Intuitive Surgical and profitable not to own Novo Nordisk and Merck. Not owning the incumbent obesity stocks combined (Eli Lilly and Novo Nordisk) continued to be a drag on performance in the full year 2024, to the tune of 150bps. In the second half of 2024, relative contribution was positive as both stocks sold off significantly.

It has been a difficult three years for healthcare investors. Our Fund has returned 1.4 percent over the three-year period, by far the weakest three-year period in the Fund's history. By comparison, the healthcare index has returned a negative 0.8 percent in the same period. Excluding the outsized index benefit from the unprecedented obesity rally, the index would have been down an estimated 8 percent over these three years. The broader equity markets² are up 20.3 percent in the same period. The unwinding of the covid windfall profit (from vaccines and testing) created a negative earnings revision cycle that should be complete by now. The underlying fundamentals (driven by innovation) are solid, and the political risks should be priced in. The current portfolio valuation is comparable to the levels observed when we launched the Fund in late 2010.

Sustainable Finance Disclosure Regulation

For the purposes of SFDR, the Fund is classified as an Article 8 Fund. This Fund promotes the environmental and social characteristics through the application of its investment strategy and the integration of environmental, social and governance (ESG) factors into the IM's fundamental bottom-up research process. However, the Fund did not commit to make a minimum proportion of sustainable investments and the investments underlying this financial product do not take into account the EU criteria for environmentally sustainable economic activities. More detailed product specific disclosures can be found in Fund's Annex IV document.

Sector Gamma AS **March 2025**

¹ MSCI World Healthcare USD

² MSCI World

INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF SECTOR CAPITAL FUNDS PLC

Report on the audit of the financial statements

Opinion on the financial statements of Sector Capital Funds Plc ("the company")

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2024 and of the profit for the financial year then ended; and
- have been properly prepared in accordance with the relevant financial reporting framework, the applicable Regulations and, in particular, with the requirements of the Companies Act 2014.

The financial statements we have audited comprise:

- the Balance Sheet;
- the Profit and Loss Account;
- the Statement of Changes in Net Assets attributable to holders of Redeemable Participating Shares;
- the Schedule of Investments; and
- the related notes 1 to 23, including a summary of significant accounting policies as set out in note 2.

The relevant financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' issued by the Financial Reporting Council ("the relevant financial reporting framework").

The applicable regulations that have been applied in their preparation is the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 and Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019 ("the applicable Regulations").

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the "*Auditor's responsibilities for the audit of the financial statements*" section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Continued on next page/

/Continued from previous page

INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF SECTOR CAPITAL FUNDS PLC

Other information

The other information comprises the information included in the Annual Report and Audited Financial Statements, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the Annual Report and Audited Financial Statements. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and otherwise comply with the Companies Act 2014, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on IAASA's website at: <https://iaasa.ie/publications/description-of-the-auditors-responsibilities-for-the-audit-of-the-financial-statements>. This description forms part of our auditor's report.

Report on other legal and regulatory requirements

Opinion on other matters prescribed by the Companies Act 2014

Based solely on the work undertaken in the course of the audit, we report that:

- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.
- In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited.
- The financial statements are in agreement with the accounting records.
- In our opinion the information given in the directors' report is consistent with the financial statements.
- In our opinion, those parts of the directors' report specified for our review, which does not include sustainability reporting when required by Part 28 of the Companies Act 2014, have been prepared in accordance with the Companies Act 2014.

Continued on next page/

/Continued from previous page

INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF SECTOR CAPITAL FUNDS PLC

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

We have nothing to report in respect of the provisions in the Companies Act 2014 which require us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions specified by law are not made.

Use of our report

This report is made solely to the company's shareholders, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's shareholders those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's shareholders as a body, for our audit work, for this report, or for the opinions we have formed.



Christian Macmanus
For and on behalf of Deloitte Ireland LLP
Chartered Accountants and Statutory Audit Firm
Deloitte & Touche House, 29 Earlsfort Terrace, Dublin 2

28 March 2025

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

BALANCE SHEET

As at 31 December 2024

	Note	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Current Assets				
Investments in financial assets held at fair value through profit or loss	7	87,486,485	445,004,587	532,491,072
Cash at bank and brokers	6	13,614,043	284,715	13,898,758
Receivable for securities sold		206,089	–	206,089
Interest receivable		1,295	23,451	24,746
Dividends receivable		33,358	663,478	696,836
Other assets		106,583	486	107,069
Total Assets		101,447,853	445,976,717	547,424,570
Current Liabilities				
Investments in financial liabilities held at fair value through profit or loss	7	–	2,245,760	2,245,760
Payable to investment manager	9	130,060	559,422	689,482
Incentive fee/performance fee	10	–	278,780	278,780
Administration fee	11	33,570	147,476	181,046
Directors' fees and expenses	12	1,349	8,806	10,155
Auditors' fee	13	12,137	12,268	24,405
Depository/Custodian fee	11	36,037	35,466	71,503
Legal fee		4,559	26,016	30,575
Interest payable		34,315	–	34,315
Capital gain tax payable		461,547	–	461,547
Equalisation credit payable		–	921,306	921,306
Trading and Research fees		–	27,127	27,127
Other creditors		7,009	37,134	44,143
Total Liabilities (excluding net assets attributable to holders of Redeemable Participating Shares)		720,583	4,299,561	5,020,144
Net assets attributable to holders of Redeemable Participating Shares	20	100,727,270	441,677,156	542,404,426

On behalf of the Board of Directors

Signed by:

Michael Boyce

E1CF5842BDAE402...

Michael Boyce, Director

Date: 26 March 2025

DocuSigned by:

Conor Walsh

60A8A96D67E74E3...

Conor Walsh, Director

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

BALANCE SHEET (Continued)

As at 31 December 2023

	Note	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Current Assets				
Investments in financial assets held at fair value through profit or loss	7	17,136,467	474,110,320	491,246,787
Cash at bank and brokers	6	2,523,984	–	2,523,984
Interest receivable		282	62,794	63,076
Dividends receivable		8,672	795,422	804,094
Other assets		188,396	601	188,997
Total Assets		19,857,801	474,969,137	494,826,938
Current Liabilities				
Investments in financial liabilities held at fair value through profit or loss	7	9,140	879,841	888,981
Bank overdraft		–	1,266,539	1,266,539
Payable for securities purchased		158,472	–	158,472
Payable to investment manager	9	29,076	349,003	378,079
Incentive fee/performance fee	10	–	158,518	158,518
Administration fee	11	20,376	202,606	222,982
Directors' fees and expenses	12	243	9,369	9,612
Auditors' fee	13	8,063	8,063	16,125
Depository/Custodian fee	11	10,109	26,800	36,909
Legal fee		–	2,607	2,607
Interest payable		3,541	–	3,541
Equalisation credit payable		–	1,211,186	1,211,186
Trading and Research fees		2,781	4,170	6,951
Other creditors		150,861	113,687	264,548
Total Liabilities (excluding net assets attributable to holders of Redeemable Participating Shares)		392,662	4,232,389	4,625,051
Net assets attributable to holders of Redeemable Participating Shares	20	19,465,139	470,736,748	490,201,887

Sector Emerging Markets Equities Fund commenced trading on 1 September 2023.

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

PROFIT AND LOSS ACCOUNT

For the financial year ended 31 December 2024

	Note	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Income				
Dividend income		532,145	11,294,333	11,826,478
Interest income		282,440	557,608	840,048
Other income		6,667	53,290	59,957
		<u>821,252</u>	<u>11,905,231</u>	<u>12,726,483</u>
Net realised gain/(loss) on:				
- investments		5,624,154	16,867,211	22,491,365
- foreign currency		(377,747)	(4,906,126)	(5,283,873)
Net change in unrealised appreciation/(depreciation) on:				
- investments		7,118,071	(3,186,509)	3,931,562
- foreign currency		(1,148,035)	(15,400,775)	(16,548,810)
Net investment gain		<u>12,037,695</u>	<u>5,279,032</u>	<u>17,316,727</u>
Expenses				
Management fee	9	(335,874)	(3,619,012)	(3,954,886)
Incentive fee/performance fee	10	–	(132,444)	(132,444)
Administration fee	11	(106,994)	(520,823)	(627,817)
Depository/Custodian fee	11	(201,344)	(182,784)	(384,128)
Directors' fees and expenses	12	(4,441)	(35,106)	(39,547)
Auditors' fee	13	(23,957)	(8,336)	(32,293)
Legal fee		(127,763)	(68,226)	(195,989)
Trading and research fees		(66,718)	(208,960)	(275,678)
Other expenses		(83,787)	(112,986)	(196,773)
Total expenses before waivers		<u>(950,878)</u>	<u>(4,888,677)</u>	<u>(5,839,555)</u>
Expense waiver from Investment Manager	9	33,356	–	33,356
Net expenses after waivers		<u>(917,522)</u>	<u>(4,888,677)</u>	<u>(5,806,199)</u>
Net gain before finance costs		<u>11,120,173</u>	<u>390,355</u>	<u>11,510,528</u>
Finance costs				
Interest expense		(356,924)	(16,374)	(373,298)
Total finance costs		<u>(356,924)</u>	<u>(16,374)</u>	<u>(373,298)</u>
Taxation				
Withholding tax and other taxation		(832,004)	(2,409,194)	(3,241,198)
Net increase/(decrease) in net assets attributable to holders of Redeemable Participating Shares resulting from operations		<u>9,931,245</u>	<u>(2,035,213)</u>	<u>7,896,032</u>

There are no recognised gains or losses for the year other than those set out in the Profit and Loss Account. All activities relate to continuing operations.

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

PROFIT AND LOSS ACCOUNT (Continued)

For the financial year ended 31 December 2023

	Note	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Income				
Dividend income		60,188	9,089,141	9,149,329
Interest income		11,843	758,776	770,619
Other income		–	59,205	59,205
		<u>72,031</u>	<u>9,907,122</u>	<u>9,979,153</u>
Net realised gain/(loss) on:				
- investments		(467,833)	15,502,570	15,034,737
- foreign currency		(46,710)	(13,173,261)	(13,219,971)
Net change in unrealised appreciation/(depreciation) on:				
- investments		1,187,050	(20,040,834)	(18,853,784)
- foreign currency		146,926	13,253,659	13,400,585
Net investment gain		<u>891,464</u>	<u>5,449,256</u>	<u>6,340,720</u>
Expenses				
Management fee	9	(29,076)	(4,596,427)	(4,625,503)
Incentive fee/performance fee	10	–	9,471	9,471
Administration fee	11	(20,376)	(546,015)	(566,391)
Depository/Custodian fee	11	(30,328)	(188,196)	(218,524)
Directors' fees and expenses	12	(464)	(39,217)	(39,681)
Auditors' fee	13	(9,411)	(9,411)	(18,822)
Legal fee		(623)	(39,666)	(40,289)
Trading and research fees		(5,285)	(172,013)	(177,298)
Other expenses		(20,595)	(199,001)	(219,596)
Total expenses before waivers		<u>(116,158)</u>	<u>(5,780,475)</u>	<u>(5,896,633)</u>
Expense waiver from Investment Manager	9	37,487	–	37,487
Net expenses after waivers		<u>(78,671)</u>	<u>(5,780,475)</u>	<u>(5,859,146)</u>
Net gain/(loss) before finance costs		<u>812,793</u>	<u>(331,219)</u>	<u>481,574</u>
Finance costs				
Interest expense		(12,640)	(3,286)	(15,926)
Total finance costs		<u>(12,640)</u>	<u>(3,286)</u>	<u>(15,926)</u>
Taxation				
Withholding tax and other taxation		(186,652)	(1,658,016)	(1,844,668)
Net increase/(decrease) in net assets attributable to holders of Redeemable Participating Shares resulting from operations		<u>613,501</u>	<u>(1,992,521)</u>	<u>(1,379,020)</u>

Sector Emerging Markets Equities Fund commenced trading on 1 September 2023.

There are no recognised gains or losses for the year other than those set out in the Profit and Loss Account. All activities relate to continuing operations.

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES

For the financial year ended 31 December 2024

	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Net Assets attributable to holders of Redeemable Participating Shares at beginning of the financial year	19,465,139	470,736,748	490,201,887
Capital transactions:			
Issue of Redeemable Participating Shares	77,118,237	104,883,795	182,002,032
Redemption of Redeemable Participating Shares	(5,787,351)	(131,921,916)	(137,709,267)
Equalisation applied	–	13,742	13,742
Net increase/(decrease) in net assets resulting from capital transactions of Redeemable Participating Shares	71,330,886	(27,024,379)	44,306,507
Net increase/(decrease) in net assets attributable to holders of Redeemable Participating Shares resulting from operations	9,931,245	(2,035,213)	7,896,032
Net Assets attributable to holders of Redeemable Participating Shares at end of the financial year	100,727,270	441,677,156	542,404,426

For the financial year ended 31 December 2023

	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Net Assets attributable to holders of Redeemable Participating Shares at beginning of the financial year	–	533,513,347	533,513,347
Capital transactions:			
Issue of Redeemable Participating Shares	23,881,449	102,036,469	125,917,918
Redemption of Redeemable Participating Shares	(5,029,811)	(162,882,998)	(167,912,809)
Equalisation applied	–	62,451	62,451
Net increase/(decrease) in net assets resulting from capital transactions of Redeemable Participating Shares	18,851,638	(60,784,078)	(41,932,440)
Net increase/(decrease) in net assets attributable to holders of Redeemable Participating Shares resulting from operations	613,501	(1,992,521)	(1,379,020)
Net Assets attributable to holders of Redeemable Participating Shares at end of the financial year	19,465,139	470,736,748	490,201,887

Sector Emerging Markets Equities Fund commenced trading on 1 September 2023.

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

SCHEDULE OF INVESTMENTS

As at 31 December 2024

Sector Emerging Markets Equities Fund

<i>Investment</i>	Units/Contracts	Fair Value as a % of Net Assets	Fair Value USD
<u>Financial Assets at Fair Value through profit or loss</u>			
<u>Equities</u>			
<u>Cayman Islands</u>			
Grab Holdings Ltd.	1,131,800	5.30%	5,342,096
Kuaishou Technology	370,800	1.96%	1,973,826
NU Holdings Ltd.	416,100	4.28%	4,310,796
Sea Ltd.	51,500	5.43%	5,464,150
Total Cayman Islands		16.97%	17,090,868
<u>China</u>			
BYD Co. Ltd.	105,500	3.59%	3,620,813
Contemporary Amperex Technology Co. Ltd.	88,125	3.19%	3,211,460
Proya Cosmetics Co. Ltd.	260,120	3.00%	3,018,415
Total China		9.78%	9,850,688
<u>India</u>			
Cartrade Tech Ltd.	248,872	4.29%	4,318,805
Cholamandalam Investment and Finance Co. Ltd.	174,884	2.40%	2,422,551
Computer Age Management Services Ltd.	36,400	2.14%	2,157,884
Jubilant FoodWorks Ltd.	251,465	2.09%	2,109,206
Medi Assist Healthcare Services	283,426	1.90%	1,908,846
Newgen Software Technologies	105,196	2.08%	2,091,049
Saregama India Ltd.	457,511	2.46%	2,473,155
SBI Cards & Payment Services Ltd.	162,733	1.25%	1,261,833
Sonata Software Ltd.	674,706	4.69%	4,723,760
Tips Industries Ltd.	223,176	1.97%	1,984,279
Titan Co. Ltd.	26,502	1.00%	1,007,023
Varun Bevarages Ltd..	601,630	4.45%	4,486,905
Total India		30.72%	30,945,296
<u>Indonesia</u>			
Indofood CBP Sukses	2,767,300	1.94%	1,955,765
PT Bank Central Asia Tbk	7,902,200	4.72%	4,750,158
Total Indonesia		6.66%	6,705,923
<u>Mauritius</u>			
MakeMyTrip Ltd.	57,700	6.43%	6,478,556
Total Mauritius		6.43%	6,478,556
<u>Netherlands</u>			
ASML Holding N.V.	3,032	2.11%	2,130,871
Total Netherlands		2.11%	2,130,871
<u>Taiwan</u>			
Taiwan Semiconductor Manufacturing Co. Ltd.	297,000	9.67%	9,738,596
Total Taiwan		9.67%	9,738,596
<u>United States</u>			
Broadcom, Inc.	7,600	1.75%	1,761,984
KLA-Tencor Corp.	4,200	2.63%	2,646,504
Total United States		4.38%	4,408,488
<u>Vietnam</u>			
Mobile World Investment Corp.	40,000	0.09%	95,743
Vietnam Technological and Commercial Joint Stock Bank	40,000	0.04%	38,689
Total Vietnam		0.13%	134,432
Total Equities		86.85%	87,483,718

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

SCHEDULE OF INVESTMENTS (Continued)

As at 31 December 2024

Sector Emerging Markets Equities Fund (Continued)

<i>Investment</i>	Units/Contracts	Fair Value as a % of Net Assets	Fair Value USD
<u>Financial Assets at Fair Value through profit or loss (continued)</u>			
Contracts-for-Difference			
<u>Vietnam</u>			
Mobile World Investment Corp.	872,900	0.00%	818
Phu Nhuan Jewelry JSC	614,600	0.00%	949
Vietnam Technological & Comm	2,639,400	0.00%	1,000
Total Vietnam		0.00%	2,767
Total Contracts-for-Difference		0.00%	2,767
Total Financial Assets at Fair Value through profit or loss		86.85%	87,486,485
Total Investments at Fair Value		86.85%	87,486,485
Cash at bank and brokers		13.52%	13,614,043
Liabilities in excess of other assets		(0.37)%	(373,258)
Total Net Assets		100.00%	100,727,270

ALL SECURITIES ARE TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL EXCHANGE LISTING OR TRADED ON A REGULATED MARKET EXCEPT FOR FORWARD FOREIGN CURRENCY CONTRACTS AND CONTRACTS-FOR-DIFFERENCE WHICH ARE FINANCIAL DERIVATIVE INSTRUMENTS

Analysis of Total Assets	% of Total Assets
Transferable securities admitted to an official exchange listing or traded on a regulated market	86.24%
Financial derivative instruments	0.00%
Other assets	13.76%
Total Assets	100.00%

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

SCHEDULE OF INVESTMENTS (Continued)

As at 31 December 2024

Sector Healthcare Value Fund

<i>Investment</i>	Units/Contracts	Fair Value as a % of Net Assets	Fair Value USD
Financial Assets at Fair Value through profit or loss			
Equities			
<u>Cayman Islands</u>			
Legend Biotech Corp.	48,495	0.36%	1,578,027
Total Cayman Islands		0.36%	1,578,027
<u>Denmark</u>			
Genmab A/S	14,500	0.68%	3,005,062
H Lundbeck A/S	2,250,000	2.92%	12,909,631
Total Denmark		3.60%	15,914,693
<u>France</u>			
BioMerieux	83,000	2.01%	8,895,463
Sanofi	24,000	0.53%	2,329,626
Total France		2.54%	11,225,089
<u>Germany</u>			
BioNTech SE	40,000	1.03%	4,558,000
Fresenius SE & Co. KGaA	275,000	2.17%	9,550,934
Total Germany		3.20%	14,108,934
<u>Ireland</u>			
Medtronic Plc	320,000	5.79%	25,561,600
Total Ireland		5.79%	25,561,600
<u>Japan</u>			
Astellas Pharma, Inc.	840,000	1.86%	8,201,705
Daiichi Sankyo Co. Ltd.	127,000	0.79%	3,516,824
Otsuka Holdings Co. Ltd.	180,000	2.23%	9,849,835
Sysmex Corp.	250,000	1.05%	4,639,380
Total Japan		5.93%	26,207,744
<u>Netherlands</u>			
Qiagen NV	203,993	2.06%	9,083,808
Total Netherlands		2.06%	9,083,808
<u>Sweden</u>			
Elektro AB	670,285	0.84%	3,709,567
Total Sweden		0.84%	3,709,567
<u>Switzerland</u>			
Roche Holding AG	112,000	7.15%	31,576,276
Sandoz Group AG	155,162	1.44%	6,363,996
Total Switzerland		8.59%	37,940,272
<u>United Kingdom</u>			
GSK Plc	1,800,000	6.87%	30,354,419
Hikma Pharmaceuticals Plc	330,000	1.87%	8,236,909
Total United Kingdom		8.74%	38,591,328
<u>United States</u>			
Amgen, Inc.	46,000	2.71%	11,989,440
Anthem, Inc.	17,279	1.44%	6,374,223
Baxter International, Inc.	158,650	1.05%	4,626,234
Becton Dickinson & Co.	76,000	3.90%	17,242,120
Biogen, Inc.	29,000	1.00%	4,434,680
BioMarin Pharmaceutical, Inc.	217,348	3.23%	14,286,284
Bio-Rad Laboratories, Inc.	16,829	1.25%	5,528,495
Bristol-Myers Squibb Co.	366,166	4.69%	20,710,349
Bruker Corp.	158,970	2.11%	9,318,821
Cardinal Health, Inc.	88,000	2.36%	10,407,760
Centene Corp.	170,000	2.33%	10,298,600
CVS Health Corp.	217,000	2.21%	9,741,130

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

SCHEDULE OF INVESTMENTS (Continued)

As at 31 December 2024

Sector Healthcare Value Fund (Continued)

<i>Investment</i>	<i>Units/Contracts</i>	<i>Fair Value as a % of Net Assets</i>	<i>Fair Value USD</i>
<u>Financial Assets at Fair Value through profit or loss (continued)</u>			
<u>Equities (continued)</u>			
<u>United States (continued)</u>			
Edwards Lifesciences Corp.	99,000	1.66%	7,328,970
Elanco Animal Health, Inc.	276,907	0.76%	3,353,344
GE HealthCare	50,000	0.89%	3,909,000
Gilead Sciences, Inc.	197,500	4.13%	18,243,075
Humana, Inc.	14,000	0.80%	3,551,940
Incyte Corp. Ltd.	197,400	3.09%	13,634,418
Ionis Pharmaceuticals, Inc.	235,842	1.87%	8,245,036
Johnson & Johnson	78,000	2.55%	11,280,360
Lantheus Holdings, Inc.	25,712	0.52%	2,300,196
Pfizer, Inc.	1,155,000	6.94%	30,642,150
PTC Therapeutics, Inc.	65,250	0.67%	2,945,385
Tandem Diabetes Care, Inc.	66,023	0.54%	2,378,148
Tenet Healthcare Corp.	22,000	0.63%	2,777,060
Zimmer Biomet Holdings, Inc.	137,714	3.29%	14,546,730
Total United States		56.62%	250,093,948
Total Equities		98.27%	434,015,010
<u>Money Market Funds</u>			
Goldman Sachs US\$ Treasury Liquid Reserves Fund	10,694,314	2.42%	10,694,314
Total Money Market Funds		2.42%	10,694,314
Net unrealised gain on forward foreign currency contracts (Note 7)		0.04%	295,263
Total Financial Assets at Fair Value through profit or loss		100.73%	445,004,587
<u>Financial Liabilities at Fair Value through profit or loss</u>			
Net unrealised loss on forward foreign currency contracts (Note 7)		(0.48)%	(2,245,760)
Total Financial Liabilities at Fair Value through profit or loss		(0.48)%	(2,245,760)
Total Investments at Fair Value		100.25%	442,758,827
Cash at bank and brokers		0.06%	284,715
Liabilities in excess of other assets		(0.31)%	(1,366,386)
Total Net Assets		100.00%	441,677,156

ALL SECURITIES ARE TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL EXCHANGE LISTING OR TRADED ON A REGULATED MARKET EXCEPT FOR FORWARD FOREIGN CURRENCY CONTRACTS AND CONTRACTS-FOR-DIFFERENCE WHICH ARE FINANCIAL DERIVATIVE INSTRUMENTS

Analysis of Total Assets	% of Total Assets
Transferable securities admitted to an official exchange listing or traded on a regulated market	99.72%
Financial derivative instruments	(0.44)%
Other assets	0.72%
Total Assets	100.00%

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS

1. Organisation and Structure

Sector Capital Funds plc (the “Company”) was incorporated and registered in Ireland with registered number 489443 and is governed by the Companies Acts 2014 as an open-ended umbrella investment company with variable capital and with segregated liability between sub-funds on 27 September 2010. The Company is authorised by the Central Bank of Ireland pursuant to European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019 (the “Regulations”).

The state of the origin of the Fund is Ireland. In Switzerland, this document may only be provided to qualified investors within the meaning of art. 10 para. 3 and 3ter CISA. In Switzerland, both the representative agent and paying agent is Banque Héritage SA, Route de Chêne 61,1211 Geneva 6, Switzerland. Investors in Switzerland can obtain documents of the funds, such as Confidential Information Memorandum and the financial reports free of charge from the Swiss representative. In Switzerland, Sector Capital AS promotes the acquisition and disposal of the Fund (FinSA Art. 3, letter c, paragraph 1.)

As at 31 December 2024, the Company has two funds in existence (31 December 2023: two), Sector Emerging Markets Equities Fund and Sector Healthcare Value Fund (the “Funds”).

Sector Emerging Markets Equities Fund commenced trading on 1 September 2023. The base currency of Sector Emerging Markets Equities Fund is United States Dollars (“USD”). As at 31 December 2024 four classes are subscribed to in the Fund (31 December 2023: three), S EUR Shares, S GBP Shares, S NOK Shares and S USD Shares.

Sector Healthcare Value Fund commenced trading on 17 November 2010. The base currency of Sector Healthcare Value Fund is USD. As at 31 December 2024, fourteen classes are subscribed to in the Fund (31 December 2023: fourteen), A EUR Shares, A NOK Shares, A USD Shares, B EUR Shares, B NOK Shares, B SEK Shares, B USD Shares, X USD Shares, X EUR Shares, Y EUR Shares, Y GBP Shares, Y USD Shares, E NOK Shares and E USD Shares.

Investment Objective

The investment objective of Sector Emerging Markets Equities Fund is to invest primarily in equity and equity related securities (such as convertible bonds which may or may not embed derivatives and/or leverage, warrants, ordinary shares including depository receipts and preferred shares) listed or traded on a recognised exchange issued by companies trading, located in or deriving the majority of their revenue or profit from emerging market countries (including but not limited to Brazil, Chile, China, India, Indonesia, Korea, Mexico, Philippines, Taiwan and South Africa) (hereinafter referred to as “Equity Participations”). Investment in Equity Participations is subject to the maximum investment of 10% in any one equity security/issuer and/or as permitted by the investment restrictions below. The Equity Participations in which the Fund will invest will not have a sectoral focus. There can be no guarantee that the investment objective of the Fund will be achieved.

The investment objective of Sector Healthcare Value Fund is to achieve attractive long term investment returns relative to the MSCI Daily TR World Net Health Care USD (the “Index”). The Index is a capitalisation weighted index that monitors the performance of health care stocks from around the world. The Fund may invest in equities and financial instruments that are not part of the Index. There can be no guarantee that the investment objective of the Fund will be achieved.

2. Summary of Significant Accounting Policies

The financial statements have been prepared in accordance with Financial Reporting Standard 102 (“FRS 102”), the Financial Reporting Standard applicable in the UK and Republic of Ireland, the Companies Acts 2014, the Regulations.

The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities at fair value through profit or loss in accordance with the European Communities (Fair Value Accounting) Regulations 2011.

The Company has availed of certain exemptions available to open-ended investment funds in FRS 102 not to prepare a cash flow statement in paragraph 7.1A of FRS 102.

The preparation of financial statements in accordance with FRS 102 requires Directors to make judgements, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the financial year. Actual results could differ from those estimates.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (continued)

The financial statements of the Company have been prepared on a going concern basis. The Company is able to meet all of its liabilities from its assets. The performance, marketability and risks of the Company are reviewed on a regular basis throughout the financial year. Therefore, the Directors believe that the Company will continue in operational existence for the foreseeable future and is financially sound. The Directors are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements of the Company.

(a) Portfolio valuation

Investment transactions

(i) Classification

The Company classifies all of its investments as financial assets or financial liabilities at fair value through profit or loss. These financial instruments are designated on the basis that their fair value can be reliably measured and their performance has been evaluated on a fair value basis in accordance with the risk management and/or investment strategy as set out in the Company's Prospectus.

(ii) Recognition

The Company recognises financial assets and financial liabilities on the date it becomes party to the contractual provisions of the instrument. Investment transactions are accounted for on a trade date basis at cost. Purchases and sales of securities are accounted for on the trade date on which the transaction takes place. Transaction costs are expensed immediately to the Profit and Loss Account and not capitalised as part of cost of the investment.

(iii) Measurement

Financial assets and financial liabilities held for trading are measured at fair value. Fair value is the amount for which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arm's length transaction.

Realised gains and losses on sales of investments are calculated on a First-In, First-Out ("FIFO") basis. Unrealised gains and losses on investments are recognised in the Profit and Loss Account. Forward foreign currency contracts and any other instruments held by the Company and traded on an exchange will be measured at fair value based on the last reported traded price on such regulated market as at the relevant valuation point.

If an investment is quoted, listed or normally dealt in on more than one market, the Directors may, in their absolute discretion, select any of such markets for the valuation purposes.

(iv) Derecognition

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the financial asset and the transfer qualifies for derecognition.

A financial liability is derecognised when the obligation specified in the contract is discharged, cancelled or expired.

(b) Forward foreign currency contracts

The unrealised gain or loss on open forward foreign currency contracts is calculated by reference to the difference between the contracted rate and the rate to close out the contract. Realised gains or losses include net gains on contracts which have been settled or offset by other contracts.

(c) Foreign exchange translation

Items included in the Company's financial statements are measured using the currency of the primary economic environment in which it operates (the "functional currency"). The functional currency of Sector Emerging Markets Equities Fund and Sector Healthcare Value Fund is the United States Dollar ("USD"), due to the fact that the majority of the Fund's assets are denominated in USD and that a substantial portion of capital is issued in USD. Each Fund has adopted its functional currency as the presentation currency for these financial statements. Assets and liabilities expressed in foreign currencies are converted into the functional currency of each Fund using the exchange rates prevailing as at the balance sheet date. Transactions in foreign currencies are translated into the Fund's functional currency at exchange rates ruling at the transaction dates. Gains and losses on foreign exchange transactions are recognised in the Profit and Loss Account in determining the result for the year.

(d) Contracts-for-difference

A contract-for-difference ("CFD") is a contract between two parties, buyer and seller, stipulating that the seller will pay to the buyer the difference between the current value of an asset (a security, instrument, basket or index) and its value at contract time. The payment flows are usually netted against each other, with the differences being paid by one party to the other. The unrealised gain or loss depends upon the prices at which the underlying financial instruments of the CFD is valued at and is included in the Profit and Loss Account.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (continued)

(e) Offsetting financial instruments

Financial assets and financial liabilities may be offset and the net amount reported in the Balance Sheet when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously. As at 31 December 2024 and 31 December 2023, no offsetting has been presented in the Balance Sheet.

(f) Income

Dividends are recognised as income on the dates that securities are first quoted “ex-dividend” to the extent information thereon is reasonably available to the Company. Interest income is accrued on a daily basis. Deposit interest is recognised as income on an accruals basis.

(g) Expenses

Operating expenses are accounted for on an accruals basis.

(h) Net asset value per share

The Net Asset Value per Share of each class is calculated by dividing the Net Asset Value attributable to a class by the number of shares of a class in issue as at the relevant valuation point.

(i) Redeemable participating shares

Shares issued by each Fund provide shareholders with the right to redeem their shares, for cash equal to their proportional share of the net asset value of the Fund and are classified as financial liabilities in accordance with FRS 102. The Funds do not meet the requirement to be classified as equity as the Fund offers different classes of shares with varying rights attached to them. The liabilities to shareholders are presented on the Balance Sheet as “Net assets attributable to holders of Redeemable Participating Shares” and are determined based on the residual assets of the Fund after deducting the Fund’s other liabilities.

(j) Amounts due from/to broker

Amounts due from/to broker relate to the outstanding amounts pending settlement on forward foreign currency contracts and upfront cash payments for fully funded contracts-for-difference.

(k) Taxation

The Company incurs dividend withholding tax and other taxation imposed by certain countries on investment income and gains on investments. Dividend income is shown gross of any non-recoverable withholding taxes, which are disclosed separately in Profit and Loss Account.

(l) Transaction costs

Transaction costs are costs incurred to acquire financial assets or financial liabilities at fair value through profit or loss. They include fees and commissions paid to agents, advisers, brokers and dealers. Transaction costs, when incurred, are immediately recognised in profit or loss as an expense. For the financial year ended 31 December 2024, Sector Emerging Markets Equities Fund incurred transaction costs of USD180,704 (31 December 2023: USD51,146) and Sector Healthcare Value Fund incurred transaction costs of USD495,404 (31 December 2023: USD185,753).

(m) Cash at bank and brokers

Cash at bank and brokers represents, cash and cash equivalents, with original maturities of three months or less held with the Depositary and brokers.

(n) Bank overdraft

Bank overdraft in the statement of financial position consists of negative cash balances on the bank accounts at the year end. Interest is charged on these bank overdraft balances.

3. Dividend and Distribution Policy

The Directors do not currently intend to pay dividends. Accordingly, the price of the shares shall rise as income and capital gains accrue.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

4. Taxation

The Company will not be liable to tax in respect of its income and gains, other than on the occurrence of a chargeable event. Generally a chargeable event arises on any distribution, redemption, repurchase, cancellation, transfer of shares or on the ending of a 'Relevant Year', a 'Relevant Year' being an eight year period beginning with the acquisition of the shares by the shareholders and each subsequent year of eight years beginning immediately after the preceding relevant year.

A chargeable event does not include:

- (i) Any transactions in relation to shares held in a recognised clearing system: or
- (ii) An exchange of shares representing a fund for another fund: or
- (iii) An exchange of shares arising on a qualifying amalgamation or reconstruction of a fund with another fund: or
- (iv) Certain exchanges of shares between spouses and former spouses.

A chargeable event will not occur in respect of shareholders who are neither resident nor ordinarily resident in Ireland and who have provided the Company with a relevant declaration to that effect.

In the absence of an appropriate declaration, the Company will be liable to Irish Tax on the occurrence of a chargeable event. There were no chargeable events during the year under review. Capital gains, dividends and interest received may be subject to withholding taxes imposed by the country of origin and such taxes may not be recoverable by the Company or its shareholders.

5. Exchange Rates

The following exchange rates (against USD) were used to convert the investments and other assets and liabilities denominated in currencies other than USD as at 31 December 2024 and 31 December 2023:

Currency	31 December 2024	31 December 2023
Australian Dollar	1.6151	-
British Pound	0.7985	0.7844
Danish Krone	7.2016	6.7484
Euro	0.9657	0.9053
Hong Kong Dollar	7.7680	-
Hungarian Forint	397.2984	346.0208
Indian Rupee	85.6164	-
Japanese Yen	157.1586	140.9841
Norwegian Krone	11.3573	10.1557
South African Rand	18.8701	-
Swedish Krona	11.0492	10.0778
Swiss Franc	0.9063	0.8417
Taiwan Dollar	32.7847	-
Vietnamese Dong	25,641.0256	-

6. Cash at bank and brokers

As at 31 December 2024 and 31 December 2023, cash balances (including overdrafts) are held with The Bank of New York Mellon SA/NV, Dublin Branch (the "Depository") and Goldman Sachs.

31 December 2024	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD
BNY Mellon	6,512,702	284,715
Goldman Sachs	7,101,341	-
	13,614,043	284,715

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

6. Cash at bank and brokers (continued)

31 December 2023	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD
BNY Mellon	1,756,579	(1,266,539)
Goldman Sachs	767,405	-
	2,523,984	(1,266,539)

Any overdrafts noted above are temporary in nature as they relate to timing differences only.

7. Financial Instruments and Associated Risks

Included in the Company's financial instruments, but not limited to, are global equities and equity related securities (including but not limited to American Depositary Receipts, Global Depositary Receipts, European Depositary Receipts and other equity based derivatives), corporate bonds and government debt obligations that shall be listed or traded on any market.

The main risks arising from the Company's financial instruments are market price, liquidity, interest rate, foreign currency and credit risks.

The Market Risk Group ("MRG") functions across all Sector Investment Manager entities and the group is responsible for defining risk management related limits ("soft limits") in addition to the investment restrictions found in the Prospectus and related supplements, in cooperation with the respective Investment Manager, securing that the Funds have a portfolio construction and risk exposure that are in line with the intentions of the individual Funds. The limits are generally related to exposure towards single positions and sectors, total portfolio exposure and Value-at-Risk ("VaR"). MRG consists of the CEO of Sector Asset Management AS (leader of MRG), Head of Fund Operations, the CCO and CEO of Sector Fund Services AS. The Head of Fund Operations has the mandate to give short term exceptions to the risk limits set by MRG if he/she finds that under certain market conditions, the limits have unintended adverse effects, for example in extreme market conditions. Such exceptions are reported to the other members of MRG and to the Group Chief Compliance Officer.

(a) Market price risk

Market price risk arises from uncertainty concerning future prices of financial instruments. The consequence might be a decline in the Fund's value. The risk related to the Funds – i.e. a combination of the probability of loss and the consequences – must be weighed against the potential gain for the Fund. To limit the risk, the Funds are both diversified and constructed through fundamental analyses of the expected behaviour and volatility of the individual instruments while following each Fund's investment objective.

Value-at-Risk

Value-at-Risk (VaR) represents the potential loss one might suffer given a defined confidence interval and time horizon. The measure is one of the main risk measures for the Company under normal market conditions.

One of the key metrics used by the Sector Group to measure market risk is VAR which encompasses currency, interest rate and price risk.

The main risk management tool for VaR calculations was Bloomberg. For all Funds, the Bloomberg VaR calculation is based on Monte Carlo simulations at a 95% confidence interval i.e. that one in every 20 days is expected to be above this measure in the long run.

For the financial year ended 31 December 2024

	Period end VaR	Gross Exposure*	Net Exposure**	lowest VaR	highest VaR	average VaR
Sector Emerging Markets Equities Fund	1.70%	93.8%	93.8%	1.33%	1.90%	1.71%
Sector Healthcare Value Fund	1.27%	98.3%	98.3%	1.23%	1.46%	1.31%

For the financial year ended 31 December 2023

	Period end VaR	Gross Exposure*	Net Exposure**	lowest VaR	highest VaR	average VaR
Sector Emerging Markets Equities Fund	1.61%	91.7%	96.1%	0.07%	2.20%	1.70%
Sector Healthcare Value Fund	1.43%	97.3%	98.2%	1.27%	1.89%	1.54%

* Exposure as % of NAV

** Net open position as % of NAV

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (continued)

(a) Market price risk (continued)

Exposure

Exposure for pure equities is equal to the fair value of the securities. The total gross exposure of each Fund is the sum of the absolute values of all long and short exposures.

(b) Interest rate risk

Interest rate risk is the risk (variability in value) borne by an interest-bearing asset, due to variability of interest rates. In general, as rates rise, the price of a fixed rate bond will fall, and vice versa. Interest rate risk is commonly measured by the bond's duration. For the financial year ended 31 December 2024 and 31 December 2023 the Funds have not invested in interest bearing assets, other than cash amounts. As at 31 December 2024 and 31 December 2023, the Funds do not have any significant fair value interest rate risk exposure.

Tables outlining the currency and interest exposure as at 31 December 2024 and 31 December 2023 are outlined in note 7(d).

(c) Liquidity risk

Liquidity risk is linked to the Funds having to realise assets in unfavourable market conditions with large losses as a consequence due to for example, redemptions in a Fund or a collapse in long asset values reducing the collateral held by counterparties leading to margin calls, if applicable. This means that there are two aspects that are monitored; what is the probability of the situation occurring and how fast can the Funds realise their positions without significant adverse effects on the value of the positions.

Liquidity of portfolio

The Company's Prospectus provides for daily subscription and redemption of shares in the Funds, therefore the Funds are exposed to a liquidity risk of meeting shareholder redemptions on a daily basis. The majority of the Funds' assets are comprised of publicly traded securities and are thus relatively easily realised. Still, with each Fund having the possibility to take positions in small cap equities, the ability of a Fund to realise assets within a short period of time without a large negative impact on the value of the assets is important. Some of the recognised exchanges on which a Fund may invest may prove to be less liquid or highly volatile from time to time. The Funds may invest a limited proportion of their assets in unquoted securities.

For the financial year ended 31 December 2024 and 31 December 2023, the Funds held very liquid assets and liquidity was monitored daily by the Investment Manager.

The reports below are snapshots of the estimated liquidity of the Funds as at 31 December 2024 and 31 December 2023:

31 December 2024

Sector Emerging Markets Equities Fund

Description	Cumulative
< 1 day	88.0%
1-2 days	95.0%
3-5 days	100.0%
1-2 weeks	100.0%
3-4 weeks	100.0%
> 4 weeks	100.0%

Sector Healthcare Value Fund

Description	Cumulative
< 1 day	91.6%
1-2 days	94.9%
3-5 days	98.0%
1-2 weeks	99.0%
3-4 weeks	100.0%
> 4 weeks	100.0%

31 December 2023

Sector Emerging Markets Equities Fund

Description	Cumulative
< 1 day	97.0%
1-2 days	100.0%
3-5 days	100.0%
1-2 weeks	100.0%
3-4 weeks	100.0%
> 4 weeks	100.0%

Sector Healthcare Value Fund

Description	Cumulative
< 1 day	91.0%
1-2 days	97.1%
3-5 days	99.0%
1-2 weeks	100.0%
3-4 weeks	100.0%
> 4 weeks	100.0%

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (continued)

(d) Foreign currency risk

Foreign currency risk is in reality a sub-group of market risk, but with its own idiosyncrasies, both with respect to a Fund's portfolio as well as the investor classes denominated in different currencies. Certain currency related transactions may, for example, be employed by the Funds in order to hedge against foreign exchange risk subject to the conditions and limits laid down by the Central Bank of Ireland. Such transactions include forward foreign currency contracts and may for example be executed in cases where an investment is in a currency other than the Fund's functional currency.

A substantial portion of the financial assets of the Funds are denominated in currencies other than the relevant Fund's functional currency with the effect that the balance sheet of the Funds can be significantly affected by currency movements.

The shares of the Company are denominated in British Pound (GBP), Euro (EUR), Norwegian Krone (NOK), Swedish Krona (SEK), Swiss Franc (CHF) and United States Dollar (USD), are issued and redeemed in those currencies. The Investment Manager may seek to hedge the foreign currency exposure of the assets attributable to the shares in order to neutralise as far as reasonably possible, the impact of fluctuations in exchange rates. This is done monthly in addition to when a Fund has more than 3% absolute return, month to date. There is no guarantee that such hedging will give returns that are equal regardless of which currency the shareholders have invested in. In addition, shareholders whose assets and liabilities are predominantly in currencies other than the currency of investment in the Company should take into account the potential risk of loss arising from fluctuations in value between CHF, EUR, GBP NOK, SEK and USD being the currency of shareholder investment, and such other currencies as invested in by the Company.

Portfolio currency exposure

The Funds trade in many different markets across the world and in many different currencies. Thus, certain assets in the portfolio may, regardless of the shares of the Fund, be invested in securities which are denominated in currencies other than CHF, EUR, GBP, NOK, SEK or USD. Consequently, the value of such assets will be affected either favourably or unfavourably by fluctuations in currency rates. The exposure towards the different currencies based on the denomination of the securities is reported daily for each Fund. For each individual Fund, action towards currency exposure in the portfolio is taken by the Investment Manager based on reported exposure of the Fund's assets.

Amounts represented below primarily are monetary assets and monetary liabilities except for investments in non-interest bearing securities, which include equities and contracts-for-difference, which are non-monetary assets.

The foreign currency exposure as at 31 December 2024 and 31 December 2023 are as follows:

31 December 2024

Sector	Cash at Bank and Brokers	Forward Currency Contracts	Investments in Interest Bearing Assets	Investments in Non-Interest Bearing Assets	Investments in Non-Interest Bearing Liabilities	Net Other Assets/ (Liabilities)	Total Net Asset Value
Emerging Markets Equities Fund							
Currency	USD	USD	USD	USD	USD	USD	USD
AUD	(3)	—	—	—	—	—	(3)
CNY	—	—	—	6,229,875	—	—	6,229,875
EUR	10,026	—	—	2,130,871	—	—	2,140,897
GBP	48,208	—	—	—	—	—	48,208
HKD	—	—	—	5,594,639	—	—	5,594,639
IDR	—	—	—	6,705,923	—	—	6,705,923
INR	1,043	—	—	30,945,296	—	—	30,946,339
NOK	14,175	—	—	—	—	—	14,175
TWD	—	—	—	9,738,596	—	28,624	9,767,220
USD	13,533,650	—	—	26,004,086	—	(401,882)	39,135,854
VND	6,944	—	—	137,199	—	—	144,143
Total	13,614,043	—	—	87,486,485	—	(373,258)	100,727,270

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (continued)

(d) Foreign currency risk (continued)

Sector	Cash at Bank and Brokers	Forward Currency Contracts	Investments in Interest Bearing Assets	Investments in Non-Interest Bearing Assets	Investments in Non-Interest Bearing Liabilities	Net Other Assets/ (Liabilities)	Total Net Asset Value
Healthcare Value Fund							
Currency	USD	USD	USD	USD	USD	USD	USD
CHF	1,302	–	–	37,940,272	–	–	37,941,574
DKK	254	–	–	15,914,693	–	–	15,914,947
EUR	67,940	(504,501)	–	20,776,023	–	–	20,339,462
GBP	13,278	–	–	38,591,328	–	313,374	38,917,980
JPY	1,942	–	–	26,207,744	–	58,411	26,268,097
NOK	455	(1,440,726)	–	–	–	–	(1,440,271)
SEK	1,034	(5,270)	–	3,709,567	–	–	3,705,331
USD	198,510	–	–	301,569,697	–	(1,738,171)	300,030,036
Total	284,715	(1,950,497)	–	444,709,324	–	(1,366,386)	441,677,156

31 December 2023

Sector	Cash at Bank and Brokers	Forward Currency Contracts	Investments in Interest Bearing Assets	Investments in Non-Interest Bearing Assets	Investments in Non-Interest Bearing Liabilities	Net Other Assets/ (Liabilities)	Total Net Asset Value
Emerging Markets Equities Fund							
Currency	USD	USD	USD	USD	USD	USD	USD
AUD	1	–	–	301,430	–	–	301,431
CNY	–	–	–	497,225	(9,140)	–	488,085
EUR	3,980	–	–	565,533	–	–	569,513
GBP	7,285	–	–	–	–	–	7,285
HKD	–	–	–	562,870	–	(40,466)	522,404
IDR	–	–	–	1,632,637	–	–	1,632,637
INR	–	–	–	7,928,298	–	–	7,928,298
KRW	–	–	–	290,625	–	(38,547)	252,078
MXN	–	–	–	576,465	–	–	576,465
NOK	(454)	–	–	–	–	–	(454)
THB	–	–	–	232,308	–	(40,008)	192,300
TWD	–	–	–	1,178,638	–	5,869	1,184,507
USD	2,513,172	–	–	3,119,603	–	(33,997)	5,598,778
VND	–	–	–	33,632	–	–	33,632
ZAR	–	–	–	217,203	–	(39,023)	178,180
Total	2,523,984	–	–	17,136,467	(9,140)	(186,172)	19,465,139

Sector	Cash at Bank and Brokers	Forward Currency Contracts	Investments in Interest Bearing Assets	Investments in Non-Interest Bearing Assets	Investments in Non-Interest Bearing Liabilities	Net Other Assets/ (Liabilities)	Total Net Asset Value
Healthcare Value Fund							
Currency	USD	USD	USD	USD	USD	USD	USD
CHF	8,721	–	–	38,679,972	–	–	38,688,693
DKK	107	–	–	8,980,862	–	–	8,980,969
EUR	42,674	131,646	–	41,220,107	–	–	41,394,427
GBP	75,802	–	–	42,074,462	–	382,914	42,533,178
JPY	13,832	–	–	37,010,430	–	115,672	37,139,934
NOK	76,238	3,367,444	–	–	–	–	3,443,682
SEK	13	18,295	–	3,882,791	–	–	3,901,099
USD	(1,483,926)	–	–	297,864,470	–	(1,725,778)	294,654,766
Total	(1,266,539)	3,517,385	–	469,713,094	–	(1,227,192)	470,736,748

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (continued)

(d) Foreign currency risk (continued)

As at 31 December 2024 the following forward foreign currency contracts were held by Sector Healthcare Value Fund.

Sector Healthcare Value Fund

Maturity Date	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss) USD
01 February 2025	BNY Mellon	EUR	(23,745)	USD	24,965	375
01 February 2025	BNY Mellon	EUR	(12,177)	USD	12,803	193
01 February 2025	BNY Mellon	EUR	(740,478)	USD	778,519	11,691
01 February 2025	BNY Mellon	EUR	(811,094)	USD	846,612	6,656
01 February 2025	BNY Mellon	EUR	(382,082)	USD	398,813	3,135
01 February 2025	BNY Mellon	EUR	(24,241,325)	USD	25,302,853	198,901
01 February 2025	BNY Mellon	USD	(880,964)	EUR	834,839	(16,418)
01 February 2025	BNY Mellon	USD	(416,042)	EUR	394,259	(7,754)
01 February 2025	BNY Mellon	USD	(26,362,048)	EUR	24,981,803	(491,275)
02 March 2025	BNY Mellon	USD	(847,733)	EUR	811,094	(6,697)
02 March 2025	BNY Mellon	USD	(399,341)	EUR	382,082	(3,154)
02 March 2025	BNY Mellon	USD	(25,336,354)	EUR	24,241,325	(200,154)
01 February 2025	BNY Mellon	NOK	(1,000,000)	USD	90,558	2,509
01 February 2025	BNY Mellon	NOK	(11,283)	USD	1,022	28
01 February 2025	BNY Mellon	NOK	(2,111,214)	USD	191,006	5,117
01 February 2025	BNY Mellon	NOK	(767,861)	USD	69,434	1,825
01 February 2025	BNY Mellon	NOK	(129,136)	USD	11,677	307
01 February 2025	BNY Mellon	NOK	(373,207)	USD	33,684	824
01 February 2025	BNY Mellon	NOK	(574,632)	USD	51,562	966
01 February 2025	BNY Mellon	NOK	(550,000)	USD	49,352	925
01 February 2025	BNY Mellon	NOK	(356,569)	USD	31,987	592
01 February 2025	BNY Mellon	NOK	(7,079,643)	USD	635,169	11,817
01 February 2025	BNY Mellon	NOK	(3,971,710)	USD	356,333	6,630
01 February 2025	BNY Mellon	NOK	(7,095,645)	USD	636,605	11,844
01 February 2025	BNY Mellon	NOK	(2,088,902)	USD	187,199	3,274
01 February 2025	BNY Mellon	NOK	(268,337)	USD	23,947	320
01 February 2025	BNY Mellon	NOK	(256,609,977)	USD	22,603,312	9,173
01 February 2025	BNY Mellon	NOK	(120,389,013)	USD	10,604,383	4,304
01 February 2025	BNY Mellon	NOK	(253,615,693)	USD	22,339,563	9,066
01 February 2025	BNY Mellon	NOK	(42,209)	USD	3,713	3
01 February 2025	BNY Mellon	NOK	(527,271)	USD	46,316	(110)
01 February 2025	BNY Mellon	NOK	(2,585,170)	USD	226,824	(797)
01 February 2025	BNY Mellon	USD	(23,816,973)	NOK	263,689,620	(599,482)
01 February 2025	BNY Mellon	USD	(12,109,233)	NOK	134,067,378	(304,793)
01 February 2025	BNY Mellon	USD	(22,282,907)	NOK	246,705,204	(560,869)
01 February 2025	BNY Mellon	USD	(724,183)	NOK	8,000,000	(19,795)
01 February 2025	BNY Mellon	USD	(8,977)	NOK	100,000	(172)
01 February 2025	BNY Mellon	USD	(226,833)	NOK	2,585,270	796
01 February 2025	BNY Mellon	USD	(439,206)	NOK	5,000,000	1,037
02 March 2025	BNY Mellon	NOK	(166,481)	USD	14,626	(31)
02 March 2025	BNY Mellon	NOK	(188,524)	USD	16,563	(35)
02 March 2025	BNY Mellon	USD	(22,603,149)	NOK	256,609,977	(10,580)
02 March 2025	BNY Mellon	USD	(10,604,306)	NOK	120,389,013	(4,963)
02 March 2025	BNY Mellon	USD	(22,339,401)	NOK	253,615,693	(10,456)
01 February 2025	BNY Mellon	SEK	(159,569)	USD	14,557	114
01 February 2025	BNY Mellon	SEK	(110,475)	USD	10,070	71
01 February 2025	BNY Mellon	SEK	(4,594,812)	USD	418,661	2,770
01 February 2025	BNY Mellon	SEK	(3,851)	USD	348	(1)
01 February 2025	BNY Mellon	USD	(446,100)	SEK	4,868,707	(5,418)
02 March 2025	BNY Mellon	SEK	(3,873)	USD	351	–
02 March 2025	BNY Mellon	USD	(419,408)	SEK	4,594,812	(2,806)
Total unrealised loss on forward foreign currency contracts						(1,950,497)

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (continued)

(d) Foreign currency risk (continued)

As at 31 December 2023 the following forward foreign currency contracts were held by Sector Healthcare Value Fund:

Sector Healthcare Value Fund

Maturity Date	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss) USD
02 January 2024	BNY Mellon	EUR	(1,092,833)	USD	1,215,318	7,935
02 January 2024	BNY Mellon	EUR	(381,151)	USD	423,870	2,767
02 January 2024	BNY Mellon	EUR	(23,819,986)	USD	26,489,730	172,954
02 January 2024	BNY Mellon	USD	(35,020)	EUR	32,195	550
02 January 2024	BNY Mellon	USD	(10,321)	EUR	9,488	161
02 January 2024	BNY Mellon	USD	(671,953)	EUR	617,740	10,538
02 January 2024	BNY Mellon	USD	(37,480)	EUR	34,242	351
02 January 2024	BNY Mellon	USD	(13,730)	EUR	12,544	129
02 January 2024	BNY Mellon	USD	(869,116)	EUR	794,039	8,153
02 January 2024	BNY Mellon	USD	(1,129,185)	EUR	1,026,396	4,797
02 January 2024	BNY Mellon	USD	(395,083)	EUR	359,119	1,679
02 January 2024	BNY Mellon	USD	(24,652,299)	EUR	22,408,207	104,717
01 February 2024	BNY Mellon	USD	(1,216,795)	EUR	1,092,833	(7,910)
01 February 2024	BNY Mellon	USD	(424,386)	EUR	381,151	(2,759)
01 February 2024	BNY Mellon	USD	(26,521,935)	EUR	23,819,986	(172,416)
02 January 2024	BNY Mellon	NOK	(219,250,443)	USD	21,709,448	118,325
02 January 2024	BNY Mellon	NOK	(356,655,439)	USD	35,314,832	192,478
02 January 2024	BNY Mellon	NOK	(164,815,997)	USD	16,319,530	88,947
02 January 2024	BNY Mellon	NOK	(2,106,616)	USD	206,309	(1,144)
02 January 2024	BNY Mellon	NOK	(1,316,093)	USD	128,206	(1,399)
02 January 2024	BNY Mellon	NOK	(1,068,404)	USD	104,078	(1,135)
02 January 2024	BNY Mellon	NOK	(296,886)	USD	28,892	(344)
02 January 2024	BNY Mellon	NOK	(188,995)	USD	18,346	(266)
02 January 2024	BNY Mellon	NOK	(2,280,174)	USD	219,190	(5,355)
02 January 2024	BNY Mellon	NOK	(2,607,211)	USD	249,269	(7,481)
02 January 2024	BNY Mellon	NOK	(722,367)	USD	69,064	(2,072)
02 January 2024	BNY Mellon	NOK	(44,688,212)	USD	4,265,892	(134,869)
02 January 2024	BNY Mellon	NOK	(61,146)	USD	5,837	(184)
02 January 2024	BNY Mellon	NOK	(749,798)	USD	70,043	(3,795)
02 January 2024	BNY Mellon	NOK	(2,740,405)	USD	254,266	(15,601)
02 January 2024	BNY Mellon	NOK	(2,017,136)	USD	187,158	(11,483)
02 January 2024	BNY Mellon	NOK	(6,052,490)	USD	557,464	(38,567)
02 January 2024	BNY Mellon	NOK	(651,310)	USD	59,989	(4,150)
02 January 2024	BNY Mellon	NOK	(1,995,857)	USD	183,594	(12,952)
02 January 2024	BNY Mellon	NOK	(734,565)	USD	67,364	(4,974)
02 January 2024	BNY Mellon	NOK	(463,225)	USD	42,409	(3,208)
02 January 2024	BNY Mellon	NOK	(3,800,484)	USD	346,311	(27,949)
02 January 2024	BNY Mellon	NOK	(137,663)	USD	12,540	(1,017)
02 January 2024	BNY Mellon	NOK	(609,748)	USD	55,545	(4,501)
02 January 2024	BNY Mellon	USD	(19,456,332)	NOK	207,054,922	933,813
02 January 2024	BNY Mellon	USD	(37,704,024)	NOK	401,247,463	1,809,618
02 January 2024	BNY Mellon	USD	(15,033,214)	NOK	159,983,957	721,524
02 January 2024	BNY Mellon	USD	(7,260)	NOK	77,721	394
02 January 2024	BNY Mellon	USD	(511,910)	NOK	5,489,756	28,705
02 January 2024	BNY Mellon	USD	(990,946)	NOK	10,626,979	55,567
02 January 2024	BNY Mellon	USD	(394,812)	NOK	4,233,996	22,139
02 January 2024	BNY Mellon	USD	(91)	NOK	1,000	7
02 January 2024	BNY Mellon	USD	(22,859)	NOK	250,000	1,760
02 January 2024	BNY Mellon	USD	(38,475)	NOK	418,320	2,720
02 January 2024	BNY Mellon	USD	(70,269)	NOK	771,148	5,671
02 January 2024	BNY Mellon	USD	(32)	NOK	350	2
02 January 2024	BNY Mellon	USD	(641,758)	NOK	6,705,765	18,606
02 January 2024	BNY Mellon	USD	(1,266,072)	NOK	13,229,257	36,705
02 January 2024	BNY Mellon	USD	(518,710)	NOK	5,420,030	15,038
02 January 2024	BNY Mellon	USD	(48,967)	NOK	500,000	271
01 February 2024	BNY Mellon	NOK	(101,598)	USD	10,008	(5)
01 February 2024	BNY Mellon	USD	(21,727,003)	NOK	219,250,443	(119,097)
01 February 2024	BNY Mellon	USD	(35,343,389)	NOK	356,655,439	(193,736)
01 February 2024	BNY Mellon	USD	(16,332,727)	NOK	164,815,997	(89,528)
01 February 2024	BNY Mellon	USD	(19,596)	NOK	198,486	(34)
02 January 2024	BNY Mellon	SEK	(1,945)	USD	187	(6)

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (continued)

(d) Foreign currency risk (continued)

Sector Healthcare Value Fund (continued)

Maturity Date	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss) USD
02 January 2024	BNY Mellon	SEK	(18,681)	USD	1,791	(63)
02 January 2024	BNY Mellon	SEK	(38,389)	USD	3,669	(141)
02 January 2024	BNY Mellon	SEK	(4,973)	USD	475	(18)
02 January 2024	BNY Mellon	SEK	(12,928)	USD	1,231	(52)
02 January 2024	BNY Mellon	SEK	(7,939,082)	USD	799,521	11,621
02 January 2024	BNY Mellon	USD	(732,808)	SEK	7,560,986	17,568
02 January 2024	BNY Mellon	USD	(19,002)	SEK	197,282	577
02 January 2024	BNY Mellon	USD	(25,155)	SEK	257,730	423
01 February 2024	BNY Mellon	SEK	(13,382)	USD	1,346	16
01 February 2024	BNY Mellon	USD	(800,523)	SEK	7,939,082	(11,630)
Total unrealised gain on forward foreign currency contracts						3,517,385

(e) Credit risk

Credit risk is the risk that a counterparty will fail to discharge an obligation or commitment that it has entered into with the Funds, resulting in a financial loss to the Funds.

The Funds are exposed to credit risk associated with counterparties with whom it trades or holds assets, and will also be exposed to the risk of settlement default. All transactions in listed securities are settled/paid for upon delivery using approved brokers. The risk of default is considered minimal, as delivery of securities sold is only made once the broker has made payment. Payment is made on a purchase once the securities have been delivered by the broker. The trade will fail if either party fails to meet its obligation.

Management of credit risk

The Investment Manager is complying with the Central Bank UCITS Regulations in terms of investment restrictions and otherwise with the investment policy of the Sub-Funds.

Exposure to credit risk

The sub-fund's maximum credit risk exposure at the Balance Sheet date is represented by the respective carrying amounts of the financial assets in the Balance Sheet with the exception of derivatives whose maximum credit risk exposure is notional exposure.

Derivative financial instruments

The Funds may also invest in financial derivative instruments for investment purposes and for efficient portfolio management ("EPM"), including (but not limited to) futures, forwards, options, contracts for difference and warrants.

All cleared derivative positions entered into on behalf of the Funds are cleared via Goldman Sachs as appointed Futures Commission Merchant ("FCMs"). Bilateral (non-cleared) derivatives face BNY as OTC credit counterparty.

Trade counterparty

The Funds mitigate counterparty risk by undertaking transactions with large and well capitalised counterparties. The Funds also seek to trade with more than one counterparty and have reduced the activity with counterparties when there have been questions raised regarding the robustness of counterparties in terms of credit risk.

Although it is the intention of the Investment Manager to follow a general policy of seeking to spread the Funds' capital at risk over a number of investments and counterparties, the Funds may at certain times hold relatively few positions with the result that a loss in any such position either to trading counterparty or settlement default could have a substantial adverse impact on a Fund's capital. The relevant Standard and Poor's ratings are as follows:

	31 December 2024	31 December 2023
The Bank of New York Mellon SA/NV	A	A
Goldman Sachs	BBB+	BBB+

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (continued)

(f) Fair value estimation

The Company used the following fair value hierarchy levels in categorising its financial instruments by source of inputs used to determine its fair value:

Level 1: The unadjusted quoted price in an active market for identical assets or liabilities that the entity can access at the measurement date.

Level 2: Inputs other than quoted prices included within Level 1 that are observable (i.e. developed using market data) for the asset or liability, either directly or indirectly.

Level 3: Inputs are unobservable (i.e. for which market data is unavailable) for the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Company. The Company considers observable data to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.

Investments classified as Level 3 are those for which a quoted price at year end was unavailable and evidence of a recent transaction at that date could not be ascertained. These investments represent collective investment schemes where the net asset value is calculated by an underlying administrator. The net asset values represent their best evidence of the fair value of these assets at year end, however due to the lack of quoted price and evidence of a recent transaction, a Level 3 classification is considered appropriate.

The level in the fair value hierarchy within which the fair value measurement is categorised is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses inputs that are unobservable, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

There were no significant transfers between levels during the financial year ended 31 December 2024 or 31 December 2023. Transfers between levels of the fair value hierarchy, for the purpose of disclosure in financial statements, are deemed to have occurred at the end of the reporting period.

The fair values of investments valued under Levels 1 to 3 for Sector Emerging Markets Equities Fund and Sector Healthcare Value Fund and at 31 December 2024 are as follows.

Sector Emerging Markets Equities Fund	Level 1 USD	Level 2 USD	Level 3 USD	Total USD
Financial assets at fair value through profit or loss				
Equity securities	87,483,718	–	–	87,483,718
Derivative instruments	–	2,767	–	2,767
Total	87,483,718	2,767	–	87,486,485

Sector Healthcare Value Fund	Level 1 USD	Level 2 USD	Level 3 USD	Total USD
Financial assets at fair value through profit or loss				
Equity securities	434,015,010	–	–	434,015,010
Derivative instruments	–	295,263	–	295,263
Money market instrument	10,694,314	–	–	10,694,314
Financial liabilities at fair value through profit or loss				
Derivative instruments	–	(2,245,760)	–	(2,245,760)
Total	444,709,324	(1,950,497)	–	442,758,827

The categories of investments above comprise:

- Equity securities (which includes equities and money market funds).
- Derivative instruments (forward foreign currency contracts and contracts for difference).

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (continued)

(f) Fair value estimation (continued)

The fair values of investments valued under Levels 1 to 3 for Sector Healthcare Value Fund as at 31 December 2023 are as follows:

Sector Emerging Markets Equities Fund	Level 1 USD	Level 2 USD	Level 3 USD	Total USD
Financial assets at fair value through profit or loss				
Equity securities	17,102,835	–	–	17,102,835
Derivative instruments	–	33,632	–	33,632
Financial liabilities at fair value through profit or loss				
Derivative instruments	–	(9,140)	–	(9,140)
Total	170,102,835	24,492	–	17,127,327

Sector Healthcare Value Fund	Level 1 USD	Level 2 USD	Level 3 USD	Total USD
Financial assets at fair value through profit or loss				
Equity securities	457,495,908	–	–	457,495,908
Derivative instruments	–	4,397,226	–	4,397,226
Money market instrument	12,217,186	–	–	12,217,186
Financial liabilities at fair value through profit or loss				
Derivative instruments	–	(879,841)	–	(879,841)
Total	469,713,094	3,517,385	–	473,230,479

The categories of investments above comprise:

- Equity securities (which includes equities and money market funds).
- Derivative instruments (forward foreign currency contracts).

8. Share Capital

The authorised share capital of the Company is 1,000,000,000,000 Shares of no par value initially designated as unclassified shares. The issued share capital of the Company is €2 represented by 2 shares (the “Subscriber Shares”) issued for the purposes of the incorporation of the Company at an issue price of €1 per Share which are fully paid up and which are beneficially owned by Sector Asset Management AS and Prieren AS.

Sector Emerging Markets Equities Fund may issue S EUR Shares, S USD Shares, S GBP Shares, S CHF Shares, S NOK Shares and S SEK Shares (the “S Shares”), I USD Shares, I GBP Shares, I EUR Shares, I CHF Shares, I NOK Shares and I SEK Shares (the “I Shares”), LI USD Shares, LI GBP Shares, LI EUR Shares, LI CHF Shares, LI NOK Shares and LI SEK Shares (the “LI Shares”), P USD Shares, P GBP Shares, P EUR Shares, P CHF Shares, P NOK Shares and P SEK Shares (the “P Shares”), and R USD Shares, R GBP Shares, R EUR Shares, R CHF Shares, R NOK Shares and R SEK Shares (the “R Shares”).

Sector Healthcare Value Fund may issue A EUR Shares, A USD Shares, A NOK Shares and A SEK Shares, (the “A Shares”), B EUR Shares, B USD Shares, B NOK Shares and B SEK (the “B Shares”), E EUR Shares, E SEK Shares, E NOK Shares and E USD Shares (the “E Shares”), X EUR Shares and X USD Shares (the “X Shares”) and Y EUR Shares, Y GBP Shares and Y USD Shares (the “Y Shares”).

On a show of hands every holder who is present in person or by proxy shall have one vote and the holders of Subscriber Shares present or in person or by proxy shall have one vote.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (continued)

The rights attached to any class may be varied or abrogated with the consent in writing of the holders of three-fourths in number of the issued Shares of that class, or with the sanction of a special resolution passed at a separate general meeting of the holders of the Shares of the class, and may be so varied or abrogated either whilst the Company is a going concern or during or in contemplation of a winding-up. The quorum at any such separate general meeting, other than an adjourned meeting, shall be two persons holding or representing by proxy at least one third of the issued Shares of the class in question and the quorum at an adjourned meeting shall be one person holding Shares of the class in question or his proxy.

The following are the share class transactions for the financial year ended 31 December 2024 were as follows:

	Sector Emerging Markets Equities Fund	Sector Healthcare Value Fund
A EUR Shares		
Shares in issue at beginning of year	–	3,276
Number of shares issued	–	–
Number of shares redeemed	–	(893)
Number in issue at end of year	<u>–</u>	<u>2,383</u>
A NOK Shares		
Shares in issue at beginning of year	–	72,267
Number of shares issued	–	15,052
Number of shares redeemed	–	(4,927)
Number in issue at end of year	<u>–</u>	<u>82,392</u>
A USD Shares		
Shares in issue at beginning of year	–	22,809
Number of shares issued	–	741
Number of shares redeemed	–	(11,793)
Number in issue at end of year	<u>–</u>	<u>11,757</u>
B EUR Shares		
Shares in issue at beginning of year	–	2,840
Number of shares issued	–	–
Number of shares redeemed	–	–
Number in issue at end of year	<u>–</u>	<u>2,840</u>
B NOK Shares		
Shares in issue at beginning of year	–	227,181
Number of shares issued	–	11,852
Number of shares redeemed	–	(163,280)
Number in issue at end of year	<u>–</u>	<u>75,753</u>
B SEK Shares		
Shares in issue at beginning of year	–	5,393
Number of shares issued	–	33
Number of shares redeemed	–	(2,303)
Number in issue at end of year	<u>–</u>	<u>3,123</u>
B USD Shares		
Shares in issue at beginning of year	–	398,864
Number of shares issued	–	91,767
Number of shares redeemed	–	(212,212)
Number in issue at end of year	<u>–</u>	<u>278,419</u>

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (continued)

	Sector Emerging Markets Equities Fund	Sector Healthcare Value Fund
Class S GBP		
Shares in issue at beginning of year	54,752	–
Number of shares issued	129,217	–
Number of shares redeemed	(9,830)	–
Number in issue at end of year	174,139	–
Class S NOK		
Shares in issue at beginning of year	985,989	–
Number of shares issued	4,689,838	–
Number of shares redeemed	(380,062)	–
Number in issue at end of year	5,295,765	–
Class S USD		
Shares in issue at beginning of year	32,392	–
Number of shares issued	15,793	–
Number of shares redeemed	–	–
Number in issue at end of year	48,185	–
E NOK Shares		
Shares in issue at beginning of year	–	1,616,963
Number of shares issued	–	1,236,261
Number of shares redeemed	–	(410,605)
Number in issue at end of year	–	2,442,619
E USD Shares		
Shares in issue at beginning of year	–	191,231
Number of shares issued	–	54,373
Number of shares redeemed	–	(47,446)
Number in issue at end of year	–	198,158
S EUR Shares		
Shares in issue at beginning of year	–	–
Number of shares issued	58,782	–
Number of shares redeemed	(475)	–
Number in issue at end of year	58,307	–
X EUR Shares		
Shares in issue at beginning of year	–	222,392
Number of shares issued	–	–
Number of shares redeemed	–	–
Number in issue at end of year	–	222,392
X USD Shares		
Shares in issue at beginning of year	–	173,198
Number of shares issued	–	4,186
Number of shares redeemed	–	(126,918)
Number in issue at end of year	–	50,466
Y EUR Shares		
Shares in issue at beginning of year	–	23,623
Number of shares issued	–	30,719
Number of shares redeemed	–	(2,610)
Number in issue at end of year	–	51,732

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (continued)

	Sector Emerging Markets Equities Fund	Sector Healthcare Value Fund
Y GBP Shares		
Shares in issue at beginning of year	–	987,741
Number of shares issued	–	235,518
Number of shares redeemed	–	(104,252)
Number in issue at end of year	–	1,119,007
Y USD Shares		
Shares in issue at beginning of year	–	585,302
Number of shares issued	–	148,035
Number of shares redeemed	–	(83,112)
Number in issue at end of year	–	650,225

The following are the share class transactions for the financial year ended 31 December 2023 were as follows:

	Sector Emerging Markets Equities Fund	Sector Healthcare Value Fund
A EUR Shares		
Shares in issue at beginning of year	–	17,009
Number of shares issued	–	282
Number of shares redeemed	–	(14,015)
Number in issue at end of year	–	3,276
A NOK Shares		
Shares in issue at beginning of year	–	81,322
Number of shares issued	–	26
Number of shares redeemed	–	(9,081)
Number in issue at end of year	–	72,267
A USD Shares		
Shares in issue at beginning of year	–	32,892
Number of shares issued	–	4,237
Number of shares redeemed	–	(14,320)
Number in issue at end of year	–	22,809
B EUR Shares		
Shares in issue at beginning of year	–	2,840
Number of shares issued	–	–
Number of shares redeemed	–	–
Number in issue at end of year	–	2,840
B NOK Shares		
Shares in issue at beginning of year	–	444,096
Number of shares issued	–	88,148
Number of shares redeemed	–	(305,063)
Number in issue at end of year	–	227,181
B SEK Shares		
Shares in issue at beginning of year	–	6,361
Number of shares issued	–	–
Number of shares redeemed	–	(968)
Number in issue at end of year	–	5,393

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (continued)

	Sector Emerging Markets Equities Fund	Sector Healthcare Value Fund
B USD Shares		
Shares in issue at beginning of year	–	437,005
Number of shares issued	–	173,150
Number of shares redeemed	–	(211,291)
Number in issue at end of year	–	398,864
Class S GBP		
Shares in issue at beginning of year	–	–
Number of shares issued	56,884	–
Number of shares redeemed	(2,132)	–
Number in issue at end of year	54,752	–
Class S NOK		
Shares in issue at beginning of year	–	–
Number of shares issued	1,024,623	–
Number of shares redeemed	(38,634)	–
Number in issue at end of year	985,989	–
Class S USD		
Shares in issue at beginning of year	–	–
Number of shares issued	77,392	–
Number of shares redeemed	(45,000)	–
Number in issue at end of year	32,392	–
E NOK Shares		
Shares in issue at beginning of year	–	1,298,204
Number of shares issued	–	1,818,765
Number of shares redeemed	–	(1,500,006)
Number in issue at end of year	–	1,616,963
E USD Shares		
Shares in issue at beginning of year	–	116,749
Number of shares issued	–	120,549
Number of shares redeemed	–	(46,067)
Number in issue at end of year	–	191,231
X EUR Shares		
Shares in issue at beginning of year	–	309,159
Number of shares issued	–	–
Number of shares redeemed	–	(86,767)
Number in issue at end of year	–	222,392
X USD Shares		
Shares in issue at beginning of year	–	235,820
Number of shares issued	–	10,085
Number of shares redeemed	–	(72,707)
Number in issue at end of year	–	173,198
Y EUR Shares		
Shares in issue at beginning of year	–	33,220
Number of shares issued	–	4,169
Number of shares redeemed	–	(13,766)
Number in issue at end of year	–	23,623

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (continued)

	Sector Emerging Markets Equities Fund	Sector Healthcare Value Fund
Y GBP Shares		
Shares in issue at beginning of year	–	998,051
Number of shares issued	–	82,744
Number of shares redeemed	–	(93,054)
Number in issue at end of year	–	987,741
Y USD Shares		
Shares in issue at beginning of year	–	563,795
Number of shares issued	–	82,876
Number of shares redeemed	–	(61,369)
Number in issue at end of year	–	585,302

9. Investment Management Fees

The Company has appointed Sector Fund Services AS as the UCITS Manager. Sector Emerging Markets Equities Fund and Sector Healthcare Value Fund pays the UCITS Manager a management fee per annum of the Net Asset Value of each of the following classes:

Sector Emerging Markets Equities Fund		Sector Healthcare Value Fund	
Class	Management Fee	Class	Management Fee
P Shares	Up to 0.30%	A Shares	Up to 1.0%
S Shares	Up to 0.55%	B Shares	Up to 2.0%
LI Shares	Up to 0.65%	E Shares	Up to 1.0%
I Shares	Up to 0.75%	X Shares	Up to 0.50%
R Shares	Up to 1.25%	Y Shares	Up to 0.40%

The Investment Manager to Sector Emerging Markets Equities Fund does not anticipate that the "Total Expense Ratio" which includes but is not limited to the management fee, administration fees and expenses, depositary fees and expenses, establishment costs of the Fund and other operating expenses of the Fund (excluding trading costs) will exceed 1.5% of the Net Asset Value of the Fund (the "TER Threshold"). If the Total Expense Ratio exceeds the TER Threshold, the Investment Manager has undertaken to discharge that proportion of the Total Expense Ratio above the TER Threshold and shall rebate the Fund accordingly.

The total management fees accrued for the financial year ended 31 December 2024 were USD3,954,886 (31 December 2023: USD4,625,503) and the net amount outstanding at 31 December 2024 was USD689,482 (31 December 2023: USD378,079).

10. Incentive Fees/Performance Fees

The Investment Manager is also entitled to receive an incentive fee/performance fee ("Incentive Fee" / "Performance Fee"), as calculated for each Fund as disclosed below. The Incentive Fee/Performance Fee will be verified by the Depositary.

Sector Emerging Markets Equities Fund

The Fund, in respect of the Class P Shares paid the Investment Manager an incentive fee (the "Incentive Fee") equal to 20% of the amount by which the Net Asset Value (before the deduction of any incentive fee) of the relevant Class exceeds the MSCI Emerging Market Net Index ("Index") adjusted Prior High Net Asset Value ("Index adjusted Prior High Net Asset Value") (as defined below). The Incentive Fee shall only be payable on the amount by which each Share outperforms the Index adjusted Prior High Net Asset Value for the relevant Share. No incentive fee will be charged in respect of the S Shares, LI Shares I Shares and R Shares.

The Incentive Fee is calculated and accrued at each Valuation Point in respect of each calendar year, in each case concluding and crystallising on the last Business Day of the relevant calendar year or, in the case of redemptions, as of each Dealing Day in due proportions to the Shares redeemed by redeeming Shareholders. The Incentive Fee (if any) will become payable to the Investment Manager within 10 Business Days of crystallisation.

The first Incentive Fee Period for any new or unlaunched Shares (that pays an Incentive Fee) shall commence from the conclusion of the relevant Initial Offer Period and cease on the last Business Day of the relevant calendar year (save in circumstances whereby a period of less than 12 months has elapsed since the creation of such new or unlaunched Shares, in which case the calculation period shall end on the last Business Day of the following calendar year).

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

10. Incentive Fees/Performance Fees (continued)

Sector Emerging Markets Equities Fund (Continued)

At the end of each calculation period, where an Incentive Fee has been paid, and only then, the Prior High Net Asset Value per Share will be reset to the Net Asset Value per Share of the Class at the end of such calculation period. For the avoidance of doubt, where the Class has underperformed, (i.e. its Net Asset Value per Share at the end of a calculation period is below the Index adjusted Prior High Net Asset Value per Share), no Incentive Fee will be payable until the underperformance is clawed back.

Sector Healthcare Value Fund

The Fund, in respect of the Class A Shares, pays the Investment Manager a fee equal to 20% of the amount by which the net asset value (before the deduction of any performance fee) of the relevant share exceeds the MSCI Daily TR World Net Healthcare USD (the “Index”). In respect of Class E Shares, a fee equal to 20% of the amount by which the net asset value (before the deduction of any performance fee) of the relevant share exceeds the Index adjusted Prior High Net Asset Value (the “Incentive Fee”). In respect of Class X Shares and Class Y Shares, a fee equal to 15% of the amount by which the net asset value (before the deduction of any performance fee) of the relevant share exceeds the Index Net Asset Value (the “Incentive Fee”).

The relevant share's subscription price or the initial issue price (where shares are issued during the initial offer year) is taken as the starting price for the purposes of determining the Incentive Fee. The Incentive Fee is accrued on a daily basis and reflected in the net asset value per share at each valuation point. The accrued Incentive Fee will only be paid to the Investment Manager once a shareholder redeems its investment in the Fund or when the Fund closes down where the performance of the relevant shares has exceeded the performance of the Index. The Incentive Fee may be payable even if the absolute return on the shareholder's investment is zero or negative. For example, if during the year of a shareholder's investment in the Fund, the net asset value per share on redemption is less than or equal to the net asset value per share that that shareholder paid on its initial subscription into the Fund, the Incentive Fee may still be payable if the net asset value per share on redemption exceeds the Index Net Asset Value per share, i.e. the Fund has outperformed the Index for the year of the shareholder's investment. No Incentive Fee will be charged in respect of the Class B Shares.

The total performance fees accrued for the financial year ended 31 December 2024 were USD132,444 and the net amount outstanding was USD278,780. During the year ended 31 December 2023, there was a reversal of accrued performance fees which resulted in a net credit of USD9,471 to the profit and loss account with USD 158,518 payable at year end.

Equalisation Credit

The equalisation credit policy is applied to the calculation of the Incentive Fee payable for certain classes in each Fund (see the Fund's relevant Supplement for further details). The Incentive Fee is calculated on a share-by-share basis so that each relevant share is charged an Incentive Fee that equates precisely with that relevant share's performance. This method of calculation ensures that (i) the Incentive Fee is charged only to those relevant shares that have appreciated in value relative to the Index, (ii) all relevant shareholders have the same amount per relevant share of the relevant class at risk in the Fund, and (iii) all shares of the same class have the same net asset value per share. If a shareholder subscribes for relevant shares at a time when the net asset value per relevant share is other than the Index Net Asset Value, certain adjustments will be made to reduce inequities that could otherwise result to the subscriber or beneficiary of the Incentive Fee. For the financial year ended 31 December 2024 an equalisation of USD(13,742) (31 December 2023: equalisation of USD(62,451)) was applied by the Company.

11. Administration Fees and Depositary/Custodian Fees

The Company has appointed BNY Mellon Fund Services (Ireland) Designated Activity Company (“BNY Mellon”) to act as Administrator, registrar and transfer agent and The Bank of New York Mellon SA/NV, Dublin Branch to act as Depositary (the “Depositary”). BNY Mellon is entitled to a shareholding services fee of USD1,875 per share class per month together with agreed upon transaction charges. The Administrator is also entitled to a financial reporting fee of up to USD7,000 per set of annual financial statements and a financial reporting fee of USD2,000 per set of interim financial statements and other out of pocket expenses out of the assets of the Fund (plus VAT). BNY Mellon is entitled to receive out of the assets of the Fund an annual administration fee, accrued and calculated on each dealing day and payable monthly in arrears and is illustrated in more detail in the table below.

- i. 0.07% of the first USD 250 million of aggregated average Net Asset Value;
- ii. 0.057% of the next USD 250 million of aggregated average Net Asset Value in excess of USD 250 million;
- iii. 0.042% of the next USD 250 million of aggregated average Net Asset Value in excess of USD 500 million;
- iv. 0.03% of the next USD 250 million of aggregated average Net Asset Value in excess of USD 750 million;
- v. 0.02% of the aggregated average Net Asset Value in excess of USD 1 billion;

subject to a minimum annual fee of USD 40,000 (plus VAT).

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

11. Administration Fees and Depositary/Custodian Fees (continued)

The Administration fee accrued for the financial year ended year was USD627,817 (31 December 2023: USD566,391) and the amount outstanding at 31 December 2024 was USD181,046 (31 December 2023: USD222,982).

The Depositary is entitled to an asset based fee per annum payable monthly together with sub-custodians' fees (which will be charged at normal commercial rates) as well as agreed upon transaction charges (which will be at normal commercial rates) and other out of pocket expenses (plus VAT) and as illustrated in the table overleaf.

- 0.02% of the first USD 200 million of aggravated average Net Asset Value; and
- 0.015% of the aggregated average Net Asset Value in excess of USD 200 million;

subject to a minimum annual fee of USD 30,000 (plus VAT).

The Depositary fee accrued for the financial year ended 31 December 2024 was USD384,128 (31 December 2023: USD218,524) and the amount outstanding at 31 December 2024 was USD71,504 (31 December 2023: USD36,909).

12. Auditors' Fees

Fees and expenses paid to the statutory auditors, Deloitte Ireland LLP, in respect of the financial year, entirely relate to the audit of the financial statements of the Company.

Audit fees charged for the financial year ended 31 December 2024 were EUR19,000 ex VAT (31 December 2023: EUR18,000). Tax compliance fees charged for the financial year ended 31 December 2024 were EUR8,550 ex VAT (31 December 2023: EUR8,600).

13. Directors' Fees and Expenses

The Directors shall be entitled to a fee in remuneration for their services at a rate to be determined from time to time by the Directors, but so that the aggregate amount of each Director's remuneration in any one year shall not exceed EUR25,000 (31 December 2023: EUR25,000) or such higher amount as may be approved by resolution of the Directors and notified to shareholders. The Directors may also be paid all travelling, hotel and other expenses, properly incurred by them, in attending and returning from meetings of the Directors or general meetings of the Company or in connection with the business of the Company. The Directors may in addition to such remuneration as aforesaid grant special remuneration to any Director who, being called upon, shall perform any special or extra services to or at the request of the Company and such remuneration will be at normal commercial rates. The Directors' fees and expenses accrued for the financial year ended 31 December 2024 was USD39,547 (31 December 2023: USD39,681) and the amount outstanding at 31 December 2024 was USD10,155 (31 December 2023: USD9,612).

14. Efficient Portfolio Management

The Company may enter into a variety of derivative instruments including, but not limited to, forward foreign exchange contracts, futures, options, swaps, contracts-for-difference, stock lending and repurchase agreements for the purposes of efficient portfolio management only, subject to the conditions and limits set out in the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2019 (the "Central Bank UCITS Regulations") and within any further limits laid down by the Central Bank of Ireland from time to time. In particular, the Funds may engage in forward foreign exchange contracts to provide protection against exchange rate risks, including cross-currency hedging, and in order to hedge foreign currency exposure of the underlying assets of the Funds into the base currency of the Funds or into a currency institutionally linked to the base currency. It is intended that the use of such forwards may reduce the currency risk in respect of the Funds and will better enable the Funds to manage its assets and liabilities. Futures contracts may be used to hedge or gain exposure to an increase in the value of an asset, market, currency, or deposit. Options may be used to hedge or achieve exposure to a particular market instead of using a physical security. Swaps may be used to achieve profit as well as to hedge existing long positions. Contracts-for-difference ("CFDs") are bilateral agreements to exchange the difference between opening and closing contracts, which represent the performance of an underlying share.

At the discretion of the Directors, the Funds may use financial derivative instruments as a primary investment policy and details of the investment policy will be set out in the applicable Supplement in accordance with the requirements of the Central Bank of Ireland.

For the year ended 31 December 2024 and 31 December 2023, the Company has utilised forward foreign currency contracts. As at 31 December 2024, all derivatives are OTC derivatives. All open derivative positions are disclosed in the schedule of investments except for forward currency contracts which are disclosed in note 7 (d) above.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

15. Directors' Interests, Connected Persons and Related Party Transactions

Fees payable to the relevant Investment Manager are disclosed in notes 9 and 10.

Depository and Administrator

Although not deemed to be related parties under FRS 102 as they do not exercise "significant influence" over the activities of the Company, the Regulations also deem a "Depository" and its "associated or group companies" to be "connected persons" to the Company. As such, The Bank of New York Mellon SA/NV, Dublin Branch, the Depository, and BNY Mellon Fund Services (Ireland) Designated Activity Company, the Administrator, are connected persons to the Company.

The Board of Directors is satisfied that there are arrangements (evidenced by written procedures) in place, to ensure that any transaction carried out with the Company by a promoter, manager, depository/custodian, investment manager and/or associated or group companies of these ("connected persons") are carried out as if negotiated at arm's length and that all such transactions are carried out in the best interests of the shareholders. The Board of Directors are satisfied that transactions with connected persons entered into during the year complied with the obligations set out in the Regulations.

31 December 2024

Key personnel	Role/Team	Fund/Class	Number of Shares held
Lars Tell/Tellaviva AS	Director/Manager	Sector Healthcare Value Fund, A NOK Shares	374
Trond Horneland/ETHO AS	Investment Manager	Sector Healthcare Value Fund, A NOK Shares	37,092
Sector Gamma AS	Investment Manager	Sector Healthcare Value Fund, B SEK Shares	118

31 December 2023

Key personnel	Role/Team	Fund/Class	Number of Shares held
Lars Tell/Tellaviva AS	Director/Manager	Sector Healthcare Value Fund, A NOK Shares	374
Trond Horneland/ETHO AS	Investment Manager	Sector Healthcare Value Fund, A NOK Shares	22,040
Sector Gamma AS	Investment Manager	Sector Healthcare Value Fund, B SEK Shares	118

As at 31 December 2024 and 31 December 2023, Sector Asset Management AS held 3 A EUR Shares, 2 A NOK Shares and 3 A USD Shares in Sector Healthcare Value Fund and 200 S USD Shares in Sector Emerging Markets Equities Fund.

16. Contingent Liabilities

The Company is established as a segregated portfolio company. As a matter of Irish law, the assets of one Fund will not be available to satisfy the liabilities of another. However, the Company is a single legal entity which may operate or have assets held on its behalf or be subject to claims in other jurisdictions which may not necessarily recognise such segregation. There is no guarantee that the courts of any jurisdiction outside Ireland will respect the limitations on liability associated with segregated portfolio companies nor is there any guarantee that the creditors of one Fund will not seek to enforce such Fund's obligations against another Fund.

As at 31 December 2024 and 31 December 2023 there were no known contingent liabilities.

17. Soft Commission

There were no soft commissions for the financial year ended 31 December 2024 and 31 December 2023.

18. IMR Regulations

In response to the CBI publishing the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) Investor Money Regulations 2015 for Fund Service Providers (the "Investor Money Regulations" or "IMR") issued in March 2015, subscription and redemption monies will (effective from 1 July 2016), be channeled through a sub-fund cash collection account in the name of the sub-fund. Pending issue of the shares and/or payment of subscription proceeds to an account in the name of the sub-fund(s), and pending payment of redemption proceeds or distributions, the relevant investor will be an unsecured creditor of the sub-fund in respect of amounts paid by or due to it. As at 31 December 2024 the Funds had no such amounts.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

19. Comparative year

The prior year comparatives are for the financial year 1 January 2023 to 31 December 2023.

20. Three Year Historical Net Asset Value

The following tables outline the number of shares outstanding and the Net Asset Value per share for each share class for the last three reporting periods.

The transactions for the financial year ended 31 December 2024 are as follows:

31 December 2024

	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD
Total Net Asset Value	100,727,270	441,677,156
Shares outstanding		
A EUR Shares	–	2,383
A NOK Shares	–	82,392
A USD Shares	–	11,757
B EUR Shares	–	2,840
B NOK Shares	–	75,753
B SEK Shares	–	3,123
B USD Shares	–	278,419
E NOK Shares	–	2,442,619
E USD Shares	–	198,518
S EUR Shares	58,307	–
S GBP Shares	174,139	–
S NOK Shares	5,295,765	–
S USD Shares	48,185	–
X EUR Shares	–	222,392
X USD Shares	–	50,466
Y EUR Shares	–	51,732
Y GBP Shares	–	1,119,007
Y USD Shares	–	650,225
Net Asset Value per Share		
A EUR Shares	–	335.88
A NOK Shares	–	3,077.66
A USD Shares	–	534.24
B EUR Shares	–	133.01
B NOK Shares	–	1,569.22
B SEK Shares	–	1,453.26
B USD Shares	–	167.52
E NOK Shares	–	102.61
E USD Shares	–	103.58
S EUR Shares	109.21	–
S GBP Shares	124.22	–
S NOK Shares	131.09	–
S USD Shares	122.77	–
X EUR Shares	–	107.83
X USD Shares	–	186.14
Y EUR Shares	–	141.75
Y GBP Shares	–	136.93
Y USD Shares	–	119.99

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

20. Three Year Historical Net Asset Value (continued)

The transactions for the financial year ended 31 December 2023 are as follows:

	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD
Total Net Asset Value	19,465,139	470,736,748
Shares outstanding		
A EUR Shares	–	3,276
A NOK Shares	–	72,267
A USD Shares	–	22,809
B EUR Shares	–	2,840
B NOK Shares	–	227,181
B SEK Shares	–	5,393
B USD Shares	–	398,864
X EUR Shares	–	222,392
X USD Shares	–	173,198
E NOK Shares	–	1,616,963
E USD Shares	–	191,231
S GBP Shares	54,752	–
S NOK Shares	985,989	–
S USD Shares	32,392	–
Y EUR Shares	–	23,623
Y GBP Shares	–	987,741
Y USD Shares	–	585,302
Net Asset Value per Share		
A EUR Shares	–	336.40
A NOK Shares	–	3,054.07
A USD Shares	–	527.22
B EUR Shares	–	135.14
B NOK Shares	–	1,581.60
B SEK Shares	–	1,480.23
B USD Shares	–	166.98
X EUR Shares	–	107.93
X USD Shares	–	182.79
E NOK Shares	–	102.70
E USD Shares	–	102.37
S GBP Shares	99.50	–
S NOK Shares	95.57	–
S USD Shares	100.09	–
Y EUR Shares	–	130.36
Y GBP Shares	–	131.97
Y USD Shares	–	117.71

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

20. Three Year Historical Net Asset Value (continued)

The transactions for the financial year ended 31 December 2022 are as follows:

	Sector Healthcare Value Fund USD
Total Net Asset Value	533,513,347
Shares outstanding	
A EUR Shares	17,009
A NOK Shares	81,322
A USD Shares	32,892
B EUR Shares	2,840
B NOK Shares	444,096
B SEK Shares	6,361
B USD Shares	437,005
X EUR Shares	309,159
X USD Shares	235,820
E NOK Shares	1,298,204
E USD Shares	116,749
Y EUR Shares	33,220
Y GBP Shares	998,051
Y USD Shares	563,795
Net Asset Value per Share	
A EUR Shares	337.04
A NOK Shares	3,049.87
A USD Shares	518.75
B EUR Shares	137.94
B NOK Shares	1,612.07
B SEK Shares	1,513.20
B USD Shares	166.57
X EUR Shares	108.53
X USD Shares	179.46
E NOK Shares	103.87
E USD Shares	101.39
Y EUR Shares	132.47
Y GBP Shares	137.31
Y USD Shares	115.56

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

NOTES TO THE FINANCIAL STATEMENTS (Continued)

21. Significant Events during the financial year

Effective 18 April 2024 Cusana Capital LLP replaced Capricorn Fund Managers Limited as Investment Manager to Sector Emerging Markets Equity Fund.

Effective 18 April 2024, a new supplement was noted by the Central Bank for Sector Emerging Markets Equities Fund noting the change in Investment Manager noted above and re-designating the fund as an Article 8 fund under the SFDR Regulations.

There were no other significant events during the financial year.

22. Significant Events after the Balance Sheet Date

On 21 February 2025, a new supplement was noted by the Central Bank of Ireland for the Sector Emerging Markets Equity Fund, the changes are noted as:

- (i) the name change of the Sector Emerging Markets Equity Fund to Cusana Emerging Markets Equities Fund;
- (ii) the minimum initial investment amount for Class I Shares has changed from USD100,000 to USD5,000;
- (iii) "Business Day" will now be any day other than a Saturday or Sunday on which commercial banks are open for business in Oslo, Dublin, and New York;
- (iv) the Valuation Point shall be the close of business in the relevant market that closes last on each Dealing Day;
- (v) the Settlement Date of subscriptions for Class LI Shares has changed to 2.00 p.m. (Irish time) on the relevant Dealing Day; and
- (vi) the Annual Management Fee for Class R Shares has increased to 1.50% per annum of the Net Asset Value attributable to the Class R Shares.

There were no other significant events after the balance sheet date.

23. Approval of Financial Statements

The financial statements were authorised for issue by the Directors on 26 March 2025.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

SIGNIFICANT PORTFOLIO MOVEMENTS (Unaudited)

In accordance with the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019, a statement of the largest changes in the composition of the Schedule of Investments during the year is provided to ensure that the shareholders can identify changes in the investments held by the Fund. These statements present the aggregate purchases and sales of an investment, exceeding 1% of the total value of purchases and sales for the year. At a minimum the largest 20 purchases and sales are listed. If the Fund enters into less than 20 purchases or sales during the year, then all transactions are presented.

Sector Emerging Markets Equities Fund

LARGEST PURCHASES	COST	LARGEST SALES	COST
	\$		\$
Taiwan Semiconductor Manufacturing Co. Ltd.	7,400,713	Central Depository Services	4,005,435
Makemytrip Ltd.	5,591,864	Lam Research Corp.	2,611,109
Nu Holdings Ltd.	5,320,187	Nvidia Corp.	2,478,835
Grab Holdings Ltd.	4,662,062	Gold Fields Ltd.	2,004,109
Sonata Software Ltd.	4,465,574	Broadcom, Inc.	1,884,411
Bank Central Asia Tbk	4,256,438	Titan Co. Ltd.	1,727,594
Sea Ltd.	4,086,948	Devy ani International Ltd.	1,626,638
Proya Cosmetics Co. Ltd.	3,690,152	Nu Holdings Ltd.	1,591,386
Kla Corp.	3,539,010	Jubilant Foodworks Ltd.	1,359,261
Varun Beverages Ltd.	3,261,346	Computer Age Management Service	1,350,815
Lam Research Corp.	2,992,198	Narayana Hrudayalaya Ltd.	1,291,372
Cholamandalam Investment And Finance Co. Ltd.	2,852,666	Taiwan Semiconductor Manufacturing Co. Ltd.	1,019,112
Cartrade Tech Ltd.	2,822,160	Sea Ltd.	969,247
Saregama India Ltd.	2,706,818	Cholamandalam Investment And Finance Co. Ltd.	964,899
Byd Co. Ltd.	2,686,597	Varun Beverages Ltd.	940,562
Asml Holding NV	2,321,583	Makemytrip Ltd.	834,272
Kuaishou Technology	2,236,659	Walmart de México y Centroamérica	819,791
Central Depository Services	2,183,904	Sbi Cards & Payment Services	623,103
Contemporary Amperex Technology Co. Ltd.	2,119,046	Arcadium Lithium Plc	492,057
Jubilant Foodworks Ltd.	2,020,282	Mega Lifesciences PCL	442,139

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

SIGNIFICANT PORTFOLIO MOVEMENTS (Unaudited) (Continued)

Sector Healthcare Value Fund

LARGEST PURCHASES	COST	LARGEST SALES	COST
	\$		\$
Goldman Sachs US\$ Treasury Liquid Reserves Fund	202,842,518	Goldman Sachs US\$ Treasury Liquid Reserves Fund	204,365,390
Roche Holding AG	44,313,896	Gilead Sciences, Inc.	39,212,618
Pfizer, Inc.	40,954,017	Sanofi	34,648,287
GSK Plc	33,245,300	GSK Plc	34,400,994
Gilead Sciences, Inc.	27,711,411	Novartis AG	34,399,284
Bristol-Myers Squibb Co.	27,679,316	Pfizer, Inc.	29,235,663
CVS Health Corp.	22,975,007	UCB SA	28,581,767
Amgen, Inc.	21,772,718	Bristol-Myers Squibb Co.	26,606,065
Becton Dickinson and Co.	20,502,187	Roche Holding AG	22,732,821
Johnson & Johnson	18,310,768	GE HealthCare	20,713,298
Centene Corp.	17,830,579	Centene Corp.	17,062,016
Sanofi	17,493,346	Biogen, Inc.	16,468,480
Novartis AG	15,845,677	CVS Health Corp.	16,292,507
BioMarin Pharmaceutical, Inc.	14,774,700	Edwards Lifesciences Corp.	14,463,589
Zimmer Biomet Holdings, Inc.	12,740,722	Incyte Corp.	13,552,658
Edwards Lifesciences Corp.	11,590,714	Tenet Healthcare Corp.	13,515,910
Medtronic Plc	11,004,851	Abbott Laboratories	11,858,330
Universal Health Services, Inc.	9,206,907	Universal Health Services, Inc.	11,264,970
Fresenius SE & Co KGaA	9,026,513	Otsuka Holdings Co. Ltd.	11,261,149
GE HealthCare	9,024,943	Sandoz Group AG	10,290,114

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2024

REMUNERATION INFORMATION (Unaudited)

Regulation 89(3A) of the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (S.I. No. 352 of 2011), as amended (the "UCITS Regulations") (as introduced pursuant to the European Union (Undertakings for Collective Investment in Transferable Securities) (Amendment) Regulations 2016 (the "UCITS V Regulations") on 21 March 2016) requires that the annual report of the Company contains certain disclosures on remuneration paid by the Company to its staff during the financial year and details of any material changes to the Company's remuneration policy made during the period.

In this regard, the following points are to be noted:

- The Company has prepared a remuneration policy outlining how it adheres to the remuneration requirements set out in the UCITS Regulations and ESMA's Guidelines on sound remuneration policies under the UCITS Directive (ESMA/2016/575) (the "Guidelines"). This policy was adopted with effect from 1 January 2018.
- No annual reviews have as yet been undertaken and no material changes have been made to the remuneration policy since 1 January 2020.

The Company has no employees or staff that it employs and pays directly. The Company has a Board of Directors, one of whom is an employee of the Sector group and receives no remuneration from the Company. The remaining two directors, each of whom is independent, receive a fixed fee only for the year ended 31 December 2024 EUR36,000 (31 December 2023: EUR36,000) in aggregate and do not receive variable remuneration. These fees are set at a level that reflects the qualifications and contribution required taking into account the Company's size, internal organisation and the nature, scope and complexity of its activities.

ANNEX IV

Template periodic disclosure for the financial products referred to in Article 8, paragraphs 1, 2 and 2a, of Regulation (EU) 2019/2088 and Article 6, first paragraph, of Regulation (EU) 2020/852

Product name: Sector Emerging Markets Equities Fund (the "Fund")

Legal entity identifier: 635400QDOJCPJCZWGM58

Environmental and/or social characteristics

Did this financial product have a sustainable investment objective?

☒ ☐ **Yes**

☐ It made **sustainable investments with an environmental objective:** ____%

☐ in economic activities that qualify as environmentally sustainable under the EU Taxonomy

☐ in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy

☐ It made **sustainable investments with a social objective:** ____%

☒ ☐ **No**

☐ It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of ____% of sustainable investments

☐ with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy

☐ with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy

☐ with a social objective

☒ It promoted E/S characteristics, but **did not make any sustainable investments**

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.



To what extent were the environmental and/or social characteristics promoted by this financial product met?

This Fund promoted the environmental and social characteristics through the application of its investment strategy and the integration of environmental, social and governance (ESG) factors into the Investment Manager's fundamental bottom-up research process for all new investment and throughout the whole holding period.

Sustainability indicators measure how the environmental or social characteristics promoted by the financial product are attained.

Sustainability analysis is critical when informing stock selection and considering risk. The Investment Manager regards sustainability as a driver of positive portfolio performance.

Sustainability is formally and explicitly integrated into the Investment Manager investment process. This ensures consideration of all material ESG matters in advance of investment decisions. Specifically, the investment checklist that the Investment Manager deploys in relation to any potential new investment includes a range of ESG questions and considerations that should also be investigated before investment.

So, ESG considerations are integral to the Investment Manager's investment analysis and are assessed in conjunction with and as part of our financial, thematic, and macro analysis and valuation work.

The ESG-related questions within the Investment Manager's investment checklist include following questions:

1. What are the long-term ESG impacts of the business?
2. Are ESG indicators improving or deteriorating?
3. Are the ESG impacts sufficiently material to stop us investing?

Full details of the ESG questions within the Investment Manager investment checklist are set out in the ESG Policy.

The following factors were considered in determining whether the Fund attained the environmental and/or social characteristics it promotes:

- 1) Exclusion list – The Investment Manager adheres to the Norges Bank exclusion list for the Fund, which comprises a list of companies which are, or have been involved, with severe environmental or social controversies. All companies on this list is entered into control systems which prevent the Fund from making investments in companies on the list at time of investment. The exclusion list is updated on an ongoing basis.
- 2) Investment aligned with Investment Manager's investment strategy and ESG Policy, which includes:
 - investment in companies with high sustainability standards which identify and manage their sustainability risks and impact on the environmental, society, and people in line with the expectations of society.
 - undertaking an assessment of the key sustainability characteristics that are material to the company and industry in which the relevant company operates in using the Investment Manager's proprietary research and analysis.
 - engaging with the management of the companies where relevant to mitigate the risks and improve sustainability performance, to encourage them to align their business models, set emission reduction targets and disclose the appropriate information regarding material climate risk and opportunities and other sustainability issues; and
 - using proxy voting to drive positive change

● **How did the sustainability indicators perform?**

As part of the investment process, the Investment Manager uses a range of both quantitative and qualitative sustainability indicators to determine the environmental and social impact of each investment within the Fund, as described above.

The Investment Manager takes into consideration differing stages of development, social norms and institutional development in different countries when assessing the acceptability of behaviour. The Investment Manager also exercises judgment in weighing the full impact of the company on the environment and society. This is particularly important to mention that ESG-related disclosure by companies may be limited, unverified and non-standardized, especially within Emerging Markets where jurisdictional frameworks tend to be less developed.

Sustainability indicators were monitored by the Investment Manager through internal research and data from external data providers, like ISS and others. This is the first reporting period, when the data was collected and mapped to the Principal Adverse Impacts indicators in the following format:

- 1) Environmental- indicators which are material to the company, specifically GHG emissions, carbon footprint, GHG intensity, waste reduction policies, water policies.

Topic	Adverse sustainability indicator	Metric	Performance	Coverage
Environmental				
Greenhouse gas emissions	PAI 1- GHG Emissions	Scope 1 GHG emissions	174.41(t)	98.5%
		Scope 2 GHG emissions	631.34 (t)	98.5%
		Scope 3 GHG emissions	16739.90 (t)	98.5%
		Total GHG emissions	17545.66 (t)	98.5%
	PAI 2 - Carbon Footprint	Carbon Footprint, Scope 1-3 (emissions per 1M EUR invested)	273.89 (t/M EUR)	98.5%
	PAI 3 - GHG intensity of investee companies	GHG intensity of investee companies	599.40 (t/M EUR)	98.2%
	PAI 4 - Exposure to companies active in the fossil fuel sector	Share of investments in companies active in the fossil fuel sector	0.00%	98.8%
	PAI 5 - Share of non-renewable consumption and production	Share of non-renewable energy consumption of investee companies from non-renewable energy sources compared to renewable energy sources, expressed as a percentage of total energy sources	26.35%	32.9%
		Share of non-renewable energy production of investee companies from non-renewable energy sources compared to renewable energy sources, expressed as a percentage of total energy sources	0.00%	98.8%
	PAI 6 - Energy consumption intensity per high impact climate sector	Energy consumption in GWh per 1M EUR of revenue of investee companies, per high impact climate sector		

	Agriculture, Forestry, and Fishing		0.00	0.0%
	Mining and Quarrying		0.02	2.1%
	Manufacturing		0.05	26.1%
	Electricity, Gas, Steam and Air Conditioning Supply		0.00	0.0%
	Water Supply, Sewerage, Waste management and remediation Activities		0.00	0.0%
	Construction		0.00	0.0%
	Wholesale and retail Trade; Repairs of Motor Vehicles and Motorcycles		0.00	0.0%
	Transportation and Storage		0.00	1.4%
	Real Estate Activities		0.00	0.0%
Biodiversity	PAI 7 - Activities negatively affecting biodiversity-sensitive areas	Share of investments in investee companies with sites/operations located in or near to biodiversity-sensitive areas where activities of those investee companies negatively affect those areas	0.00%	95.9%
Water	PAI 8 - Emissions to water	Tons of emissions to water generated by investee companies per million EUR invested, expressed as a weighted average	0.00 (t)	0.0%
Waste	PAI 9 - Hazardous waste and radioactive waste ratio	Tons of hazardous waste and radioactive waste generated by investee companies per million EUR invested, expressed as a weighted average	0.09 (t)	37.9%

Principal adverse impacts are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.

- 2) **Social:** The Investment Manager's sustainability analysis covers also analysis of human and labour rights. A series of ESG questions within the Investment Manager's company "checklist" are used to analyse the risk and challenges affecting the companies with regards to human and labour rights. The Investment Manager aims to assess the substance of the businesses impact on society, via a balanced assessment and using its local market and industry understanding. The Investment Manager expects companies to adhere to local laws and regulations, but where these are lacking or underdeveloped, the Investment Manager expects companies to have a higher standards in-line with international law.

Topic Social	Adverse sustainability indicator	Metric	Performance	Coverage
	PAI 10 - Violations of UN Global Compact principles and Organization for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises	Share of investments in investee companies that have been involved in violations of the UNGC principles or OECD Guidelines for Multinational Enterprises	0.00%	95.9%
	PAI 11 - Lack of processes and compliance mechanisms to monitor compliance with UN Global Compact principles and OECD Guidelines for Multinational Enterprises	Share of investments in investee companies without policies to monitor compliance with the UNGC principles or OECD Guidelines for Multinational Enterprises or grievance/complaints handling mechanisms to address violations of the UNGC principles or OECD Guidelines for Multinational Enterprises	19.7%	56.3%

	PAI 12 - Unadjusted gender pay gap	Average unadjusted gender pay gap of investee companies	0.11%	2.7%
	PAI 13 - Board gender diversity	Average ratio of female to male board members in investee companies, expressed as a percentage of all board members	17.37%	85.6%
	PAI 14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)	Share of investments in investee companies involved in the manufacture or selling of controversial weapons	0.00%	98.0%

● **...and compared to previous periods?**

N/A – this is the first reporting period.

● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objectives?**

N/A – the Fund did not make any sustainable investments in the reporting period.

● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

N/A – the Fund did not make any sustainable investments in the reporting period.

— — How were the indicators for adverse impacts on sustainability factors taken into account?

N/A

— — Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:

The EU Taxonomy sets out a “do not significant harm” principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.

The “do no significant harm” principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

Any other sustainable investments must also not significantly harm any environmental or social objectives.

N/A - the Fund did not make any sustainable investments in the reporting period.



How did this financial product consider principal adverse impacts on sustainability factors?

The Investment Manager has integrated consideration of the PAIs in its fundamental, bottom-up investment analysis and process, ensuring its integration throughout the entire investment cycle, which is described in detail in ESG policy. When considering principal adverse impacts, the Investment Manager also takes into consideration differing stages of development, social norms and institutional development in different countries when assessing the acceptability of behaviour. The Investment Manager also exercises judgment in weighing the full impact of the company on the environment and society.

The Investment Manager assesses good governance practices of investee companies as part of the Investment Manager's due diligence process and analysis in accordance with the Fund's Core ESG principles, as set out above. Investee companies are assessed against a variety of factors and metrics, including sound management structures, employee relations, related party transactions, remuneration of staff and tax compliance.

The Investment Manager actively engages with its investee companies where the team perceive their activities or failure to consider fully the impact of sustainability as a risk to shareholder value. The Investment Manager's emerging markets investment team will be responsible for any company engagement. Engagement is a fundamental part of the process and is normally undertaken through correspondence or, if necessary, company meetings. The Investment Manager will always seek to offer solutions for management and will be highly respectful of the issues they face when submitting those proposed solutions. However, if within the medium term the Investment Manager thinks that the company is not doing enough to remedy situations of concern, the Investment Manager will withdraw its support for the investment.

The Investment Manager monitors and screens on a quarterly basis fund-level Principal Adverse Impact indicators (PAI) and reports through the reference period, using data from ISS Governance.



What were the top investments of this financial product?

Average for the calendar year 2024 (daily average 01/01/2024 to 31/12/2024)

Largest investments	Sector	% Assets	Country
TSMC	Information	8.02	TAIWAN
Varun Beverages Ltd	Consumer Staples	6.20	INDIA
NU Holdings Ltd/Cayman Island	Financials	6.03	BRAZIL
Bank Central Asia Tbk PT	Financials	4.66	INDONESIA
MakeMyTrip Ltd	Consumer	4.09	INDIA
Sonata Software Ltd	Information	3.91	INDIA
Sea Ltd	Communication	3.67	SINGAPORE
Cholamandalam Investment and	Financials	3.57	INDIA

The list includes the investments constituting the **greatest proportion of investments** of the financial product during the reference period which is: 01.01.2024 – 31.12.2024

Central Depository Services	Financials	3.24	INDIA
Computer Age Management Servi	Industrials	3.14	INDIA
Titan Co Ltd	Consumer	2.97	INDIA
Indofood CBP Sukses Makmur Tb	Consumer Staples	2.92	INDONESIA
Jubilant Foodworks Ltd	Consumer	2.85	INDIA
Broadcom Inc	Information	2.73	UNITED STATES
CATL	Industrials	2.66	CHINA



What was the proportion of sustainability-related investments?

● What was the asset allocation?

The Investment Manager implements the ESG approach in relation to all new potential investments, which entails that 100% of the new investments will be aligned with the promoted environmental and social characteristics. The approach, as outlined above, include an ESG due diligence and analysis of all potential investments. Existing investments are continuously screened and rated internally using the Investment Manager's proprietary research and framework.

Average for the calendar year 2024 (daily average 01/01/2024 to 31/12/2024):


- The proportion of investment aligned with the environmental and social characteristics promoted by the Fund was 96.2% during the reference period.

A company was considered aligned with the environmental and social characteristics of the Fund if the company was not on the exclusions list and if the Investment Manager was able to obtain their own analysis.

- Cash in the Fund was 3.8%.

However, the Fund do not commit to make a minimum proportion of sustainable investments as defines in the SFDR Article 2(17), and/or environmentally sustainable investments in economic activities that comply with the criteria in Article 3 in regulation (EU) 2020/852 on the establishment of a framework to facilitate sustainable investment (the Taxonomy regulation).

Asset allocation
describes the
share of
investments in
specific assets.



● *In which economic sectors were the investments made?*

Average for the calendar year 2024 (daily average 01/01/2024 to 31/12/2024)

Sectors	%
Financials	22.5
Information Technology	21.3
Consumer Discretionary	21.1
Consumer Staples	11.7
Communication Services	7.3
Industrials	6.8
Materials	2.9
Health Care	2.5
Cash	3.8



To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?


The Fund does not commit to invest any proportion of its assets in environmentally sustainable economic activities aligned with the EU Taxonomy. Accordingly, the level of EU Taxonomy aligned investments were zero per cent (0%).

● **Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy¹?**

- ☐ Yes:
- ☐ In fossil gas ☐ In nuclear energy
- ☒ No

The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.*

N/A – the Fund did not commit to holding Taxonomy-aligned investments.



* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures.

● **What was the share of investments made in transitional and enabling activities?**

N/A – the Fund did not commit to holding Taxonomy-aligned investments.

¹ Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objective - see explanatory note in the left hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

- **How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods**

N/A – the Fund did not commit to holding Taxonomy-aligned investments.



are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.



What was the share of sustainable investments with an environmental objective not aligned with the EU Taxonomy

N/A – the Fund did not commit to holding sustainable investments with an environmental objective not aligned with the EU-Taxonomy.



What was the share of socially sustainable investments?

N/A – the Fund did not commit to holding socially sustainable investments.



What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?

The investments included under “Other” section were cash or other holdings, which have been retained for liquidity, hedging and/or cash management purposes. No minimum environmental or social safeguards were in place in relation to such holdings.



What actions have been taken to meet the environmental and/or social characteristics during the reference period?

The Investment Manager monitors investee companies' alignment with its ESG Policy as well as monitoring their broader ESG profiles through the Investment Manager's fundamental analysis of the investee companies, third party research and data providers. The Investment Manager also assesses company's corporate disclosures, including their financial and sustainability reports.

The Investment Manager engages with all the investee companies regarding ESG matters considered material to that specific company. Engagement is a fundamental part of the investment process. The Investment Manager intends inter alia, to engage with the management teams, board members and other stakeholders of its underlying portfolio companies when it believes that such engagement can positively influence any processes aimed at enhancing the value of an investment.



How did this financial product perform compared to the reference benchmark?

N/A – the Fund did not designate a reference benchmark the purpose of attaining the environmental or social characteristics promoted.

Reference benchmarks are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

- *How does the reference benchmark differ from a broad market index?*

N/A

- *How did this financial product perform with regard to the sustainability indicators to determine the alignment of the reference benchmark with the environmental or social characteristics promoted?*

N/A

- *How did this financial product perform compared with the reference benchmark?*

N/A

- *How did this financial product perform compared with the broad market index?*

N/A

Periodic disclosure for the financial products referred to in Article 8, paragraphs 1, 2 and 2a, of Regulation (EU) 2019/2088 and Article 6, first paragraph, of Regulation (EU) 2020/852

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

Product name: Sector Healthcare Value Fund (the "Fund")

Legal entity identifier: 635400AIUDDOVUMNJX04

Environmental and/or social characteristics

Did this financial product have a sustainable investment objective?

☒ ☒ ☐ Yes

☐ It made **sustainable investments with an environmental objective**: ____%

☐ in economic activities that qualify as environmentally sustainable under the EU Taxonomy

☐ in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy

☐ It made **sustainable investments with a social objective**: ____%

☒ ☐ ☒ No

☐ It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of ____% of sustainable investments

☐ with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy

☐ with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy

☐ with a social objective

☒ It promoted E/S characteristics, but **did not make any sustainable investments**

To what extent were the environmental and/or social characteristics promoted by this financial product met?

The following environmental and social characteristics were promoted by the Fund:

Environmental Characteristics

• Biodiversity and the environment

Social characteristics

• Ethical marketing and pricing practices

• Health and Safety

• Product Safety and Integrity

Performance in relation to these environmental and social characteristics was measured through the use of an exclusion list and third-party ESG data analysis.



Sustainability indicators measure how the environmental or social characteristics promoted by the financial product are attained.

How did the sustainability indicators perform?

As part of the investment process, the Investment Manager considered a variety of sustainability indicators to measure the environmental and social characteristics promoted by the Fund. These sustainability indicators are as follows:

(i) Exclusion List

To ensure that the environmental and social characteristics promoted by the Fund were attained, the Investment Manager applied specific investment exclusions when determining what investments to make as part of the portfolio construction.

The Investment Manager adhered to the Norges Bank observation and exclusion of companies list (the "**Exclusion List**"), ensuring that the Fund did not invest in companies in contravention of the Exclusion List. The Exclusion list can be found at <https://www.nbim.no/en/the-fund/responsible-investment/exclusion-of-companies>

(ii) Third-party ESG data analysis

In addition to integrating the aforementioned Exclusion List into the portfolio construction process, the Investment Manager measured portfolio companies using information provided by a third-party ESG data provider which allocated a specific ESG rating to company holdings in the Fund and investee companies that the Investment Manager was looking at as potential investments (the "**ESG Rating**").

Investee companies were assigned a value creation score where the company's resilience to long-term industry material environmental, social and governance risks forms part of the value score through the use of third party ESG ratings. Industry ESG leaders were positively impacted, whereas laggards were negatively impacted in the Investment Manager's value creation score.

This ESG Rating measured an investee company's resilience to long-term industry material environmental, social and governance risks. A rules-based methodology was used to identify companies that are (i) industry leaders (ii) average or (iii) laggards, according to their exposure to ESG risks and how well they manage those risks relative to peers.

The Investment Manager also tracked and reported on the performance of the above sustainability indicators namely, (i) the adherence to the Exclusion List applied to the Fund; and (ii) the ESG Rating.

These sustainability indicators were used to measure the attainment of each of the environmental and social characteristics promoted by the Fund.


The table below shows the weighted performance for the positions held in the Fund by the ESG Rating for the reference period.

Rating	Sector Healthcare Value Fund	
	Weight	Return
AAA	8.2%	5.2%
AA	28.7%	-1.0%
A	31.3%	5.4%
BBB	12.7%	-10.0%
BB	7.9%	-7.1%
CCC	0.0%	30.7%
Not Classified	11.2%	16.7%

Principal adverse impacts are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.

● **and compared to previous periods?**

The Investment Manager has seen the increasing number of companies disclosing their sustainability information and thus being rated by third-party vendors and research providers. However, we still see over representation of small and medium enterprises in the “Unclassified” category. This is due to limited resources, such as budget constraints and fewer staff. It is often difficult for these companies to dedicate the necessary time and expertise to developing comprehensive sustainability reports. The Investment Manager recognizes the importance of reliable, consistent, and comparable information regarding various sustainability factors which can enable the team to price sustainability risk correctly. The Investment Manager assesses the quality of all external data on an ongoing basis.



The Investment Manager believes the ESG ratings had limited impact on the performance.

● ***What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objectives?***

N/A – the Fund did not make any sustainable investments in the reporting period.

● ***How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?***

N/A – the Fund did not make any sustainable investments in the reporting period.

How were the indicators for adverse impacts on sustainability factors taken into account?

N/A

Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:

N/A - the Fund did not make any sustainable investments in the reporting period.

The EU Taxonomy sets out a “do not significant harm” principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.

The “do no significant harm” principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

Any other sustainable investments must also not significantly harm any environmental or social objectives.



How did this financial product consider principal adverse impacts on sustainability factors?

N/A – the Investment Manager did not consider PAIs with respect to the Fund.



What were the top investments of this financial product?

Average for the calendar year 2024 (daily average 01.01.2024 to 31.12.2024)

Largest investments	Sector	% Assets	Country
GSK PLC	Healthcare	7.0	United Kingdom
Medtronic PLC	Healthcare	5.4	Ireland
Pfizer INC	Healthcare	5.4	United States
Roche Holding	Healthcare	5.2	Switzerland
Bristol-Myers	Healthcare	4.9	United States
Gilead Sciences	Healthcare	4.5	United States
Incyte corp	Healthcare	3.2	United States
Sanofi	Healthcare	3.2	France
CVS Health	Healthcare	3.0	United States
Cardinal Health	Healthcare	2.7	United States
Elevance health	Healthcare	2.6	United States
UCB SA	Healthcare	2.6	Belgium
Otsuka Holdings	Healthcare	2.5	Japan
H Lundbeck	Healthcare	2.5	Denmark
Zimmer Biomet holdings	Healthcare	2.4	United States

The list includes the investments constituting the **greatest proportion of investments** of the financial product during the reference period which is: 01.01.2024 – 31.12.2024



What was the proportion of sustainability-related investments?

What was the asset allocation?

The proportion of investments aligned with the environmental and social characteristics promoted by the Fund was 88.8% during the reference period.

Asset allocation

describes the share of investments in specific assets.


A company was considered aligned with the environmental and social characteristics of the Fund if the company was not on the aforementioned exclusion list and if the Investment Manager was able to obtain the third party ESG-rating. The ESG-rating impacted the portfolio weight by punishing laggards and rewarding winners in our scorecard model which was used as input to the Funds investment portfolio process.

The Fund aimed to hold a minimum of 80% investments that were aligned with the environmental or social characteristics promoted by the Fund.

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.

Transitional activities are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.



In which economic sectors were the investments made?

Average for the calendar year 2024 (daily average 01.01.2024 to 31.12.2024)

GICS	% Assets
Healthcare	97.5
Cash	2.5



To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

N/A – the Fund did not commit to holding Taxonomy-aligned investments.

Taxonomy-aligned activities are expressed as a share of:

- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure** (CapEx) showing the green investments made by investee companies, e.g. for a transition to a green economy.
- **operational expenditure** (OpEx) reflecting green operational activities of investee companies.

Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy¹?


Yes:

In fossil gas In nuclear energy

No

The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.

N/A – the Fund did not commit to holding Taxonomy-aligned investments.



* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures.

What was the share of investments made in transitional and enabling activities?

N/A – the Fund did not commit to holding Taxonomy-aligned investments.

¹ Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objective - see explanatory note in the left hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

- **How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?**

N/A – the Fund did not commit to holding Taxonomy-aligned investments.



What was the share of sustainable investments with an environmental objective not aligned with the EU Taxonomy?

N/A – the Fund did not commit to holding sustainable investments with an environmental objective not aligned with the EU-Taxonomy.



What was the share of socially sustainable investments?

N/A – the Fund did not commit to holding socially sustainable investments.



What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?

“Other” included the remaining investments of the Fund which were neither aligned with the environmental or social characteristics, nor qualified as sustainable investments. This “Other” section in the Fund included companies that were not well covered by third party ESG rating agencies, thereby reducing the Investment Manager’s visibility on ESG matters in respect of these companies. Typically newer and smaller market capitalization companies fall into this category.

The “Other” section in the Fund also included cash that was held for a number of reasons that the Investment Manager felt was beneficial to the Fund, such as, but not limited to, achieving risk management, and/or to ensure adequate liquidity and hedging.

A lack of disclosure and visibility on ESG matters impacted the capital allocation towards this “Other” segment but the investee companies that comprise the “Other” were not strictly excluded from the Fund as the Investment Manager believed there were mis-pricings that could be capitalised on within this segment.

As noted above, the Fund was invested in compliance with the Exclusion List, on a continuous basis. The Investment Manager believes that compliance with the Exclusion List prevents investments in companies that breach environmental and/or social minimum standards and ensures that the Fund can successfully promote its environmental and social characteristics. By adhering to the Exclusion List, the Investment Manager ensured that robust environmental and social safeguards were in place.



are

sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.



What actions have been taken to meet the environmental and/or social characteristics during the reference period?

The Fund was managed in-line with the investment objective and the following actions were taken:

(i) Exclusion List:

To ensure that the environmental and social characteristics promoted by the Fund were attained, the Fund applied the Exclusion List referenced above, which placed limitations on the investable universe.

(ii) Integrating third-party ESG analysis:

In addition to integrating the aforementioned Exclusion List into the portfolio construction process, the Investment Manager measured all portfolio companies using the aforementioned ESG Rating. The ESG Rating was used to measure the environmental and social characteristics promoted by the Fund.

As noted above, this ESG Rating was designed to measure an investee company’s resilience to long-term industry material environmental, social and governance risks. A rules-based methodology was used to identify companies that were (i) industry leaders (ii) average or (iii) laggards, according to their exposure to ESG risks and how well they manage those risks relative to peers.

Investee companies were assigned a value creation score where the company's resilience to long-term industry material environmental, social and governance risks forms part of the value score through the use of third party ESG ratings. Industry ESG leaders were positively impacted, whereas laggards were negatively impacted in the Investment Manager's value creation score.



How did *this financial product* perform compared to the reference benchmark?

N/A – the Fund did not designate a reference benchmark the purpose of attaining the environmental or social characteristics promoted.

● **How does the reference benchmark differ from a broad market index?**

N/A

● **How did *this financial product* perform with regard to the sustainability indicators to determine the alignment of the reference benchmark with the environmental or social characteristics promoted?**

N/A

● **How did *this financial product* perform compared with the reference benchmark?**

N/A

● **How did *this financial product* perform compared with the broad market index?**

N/A

Reference benchmarks are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.